NR3C1Glucocorticoid receptor
Receptor for glucocorticoids (GC).
UniProt locations Cytoplasm · Nucleus · Mitochondrion · Cytoplasm, cytoskeleton, spindle · Cytoplasm, cytoskeleton, microtubule organizing center, centrosome · Chromosome · Nucleus, nucleoplasm
Function
Receptor for glucocorticoids (GC) [103, 74]. Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modulator of other transcription factors [73]. Affects inflammatory responses, cellular proliferation and differentiation in target tissues.
Involved in chromatin remodeling [22]. Plays a role in rapid mRNA degradation by binding to the 5' UTR of target mRNAs and interacting with PNRC2 in a ligand-dependent manner which recruits the RNA helicase UPF1 and the mRNA-decapping enzyme DCP1A, leading to RNA decay [68]. Could act as a coactivator for STAT5-dependent transcription upon growth hormone (GH) stimulation and could reveal an essential role of hepatic GR in the control of body growth (By similarity)
Evidence & references
- ECO:0000250 UniProtKB:P06537
- ECO:0000269 PubMed:25775514 ↗
- ECO:0000269 PubMed:27120390 ↗
- ECO:0000269 PubMed:28139699 ↗
- ECO:0000269 PubMed:37478846 ↗
- ECO:0000269 PubMed:9590696 ↗
Complete source annotation
{
"texts": [
{
"evidences": [
{
"evidenceCode": "ECO:0000250",
"source": "UniProtKB",
"id": "P06537"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "25775514"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "27120390"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "28139699"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "37478846"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "9590696"
}
],
"value": "Receptor for glucocorticoids (GC) (PubMed:27120390, PubMed:37478846). Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modulator of other transcription factors (PubMed:28139699). Affects inflammatory responses, cellular proliferation and differentiation in target tissues. Involved in chromatin remodeling (PubMed:9590696). Plays a role in rapid mRNA degradation by binding to the 5' UTR of target mRNAs and interacting with PNRC2 in a ligand-dependent manner which recruits the RNA helicase UPF1 and the mRNA-decapping enzyme DCP1A, leading to RNA decay (PubMed:25775514). Could act as a coactivator for STAT5-dependent transcription upon growth hormone (GH) stimulation and could reveal an essential role of hepatic GR in the control of body growth (By similarity)"
}
],
"commentType": "FUNCTION"
}Has transcriptional activation and repression activity [31, 94, 39, 96, 50, 49, 53, 56, 64]. Mediates glucocorticoid-induced apoptosis [61]. Promotes accurate chromosome segregation during mitosis [69].
May act as a tumor suppressor [69]. May play a negative role in adipogenesis through the regulation of lipolytic and antilipogenic gene expression (By similarity)
Evidence & references
- ECO:0000250 UniProtKB:P06537
- ECO:0000269 PubMed:11435610 ↗
- ECO:0000269 PubMed:15769988 ↗
- ECO:0000269 PubMed:15866175 ↗
- ECO:0000269 PubMed:17635946 ↗
- ECO:0000269 PubMed:19141540 ↗
- ECO:0000269 PubMed:19248771 ↗
- ECO:0000269 PubMed:20484466 ↗
- ECO:0000269 PubMed:21664385 ↗
- ECO:0000269 PubMed:23303127 ↗
- ECO:0000269 PubMed:23820903 ↗
- ECO:0000269 PubMed:25847991 ↗
Complete source annotation
{
"texts": [
{
"evidences": [
{
"evidenceCode": "ECO:0000250",
"source": "UniProtKB",
"id": "P06537"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "11435610"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "15769988"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "15866175"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "17635946"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "19141540"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "19248771"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "20484466"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "21664385"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "23303127"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "23820903"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "25847991"
}
],
"value": "Has transcriptional activation and repression activity (PubMed:11435610, PubMed:15769988, PubMed:15866175, PubMed:17635946, PubMed:19141540, PubMed:19248771, PubMed:20484466, PubMed:21664385, PubMed:23820903). Mediates glucocorticoid-induced apoptosis (PubMed:23303127). Promotes accurate chromosome segregation during mitosis (PubMed:25847991). May act as a tumor suppressor (PubMed:25847991). May play a negative role in adipogenesis through the regulation of lipolytic and antilipogenic gene expression (By similarity)"
}
],
"commentType": "FUNCTION",
"molecule": "Isoform Alpha"
}Acts as a dominant negative inhibitor of isoform Alpha [53, 18, 19]. Has intrinsic transcriptional activity independent of isoform Alpha when both isoforms are coexpressed [49, 67]. Loses this transcription modulator function on its own [53].
Has no hormone-binding activity [19]. May play a role in controlling glucose metabolism by maintaining insulin sensitivity (By similarity). Reduces hepatic gluconeogenesis through down-regulation of PEPCK in an isoform Alpha-dependent manner [67].
Directly regulates STAT1 expression in isoform Alpha-independent manner [67]
Evidence & references
- ECO:0000250 UniProtKB:P06537
- ECO:0000269 PubMed:19248771 ↗
- ECO:0000269 PubMed:20484466 ↗
- ECO:0000269 PubMed:26711253 ↗
- ECO:0000269 PubMed:7769088 ↗
- ECO:0000269 PubMed:8621628 ↗
Complete source annotation
{
"texts": [
{
"evidences": [
{
"evidenceCode": "ECO:0000250",
"source": "UniProtKB",
"id": "P06537"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "19248771"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "20484466"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "26711253"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "7769088"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "8621628"
}
],
"value": "Acts as a dominant negative inhibitor of isoform Alpha (PubMed:20484466, PubMed:7769088, PubMed:8621628). Has intrinsic transcriptional activity independent of isoform Alpha when both isoforms are coexpressed (PubMed:19248771, PubMed:26711253). Loses this transcription modulator function on its own (PubMed:20484466). Has no hormone-binding activity (PubMed:8621628). May play a role in controlling glucose metabolism by maintaining insulin sensitivity (By similarity). Reduces hepatic gluconeogenesis through down-regulation of PEPCK in an isoform Alpha-dependent manner (PubMed:26711253). Directly regulates STAT1 expression in isoform Alpha-independent manner (PubMed:26711253)"
}
],
"commentType": "FUNCTION",
"molecule": "Isoform Beta"
}Has lower transcriptional activation activity than isoform Alpha. Exerts a dominant negative effect on isoform Alpha trans-repression mechanism [53]
Evidence & references
No separate evidence record is supplied for this statement.
Complete source annotation
{
"texts": [
{
"value": "Has lower transcriptional activation activity than isoform Alpha. Exerts a dominant negative effect on isoform Alpha trans-repression mechanism (PubMed:20484466)"
}
],
"commentType": "FUNCTION",
"molecule": "Isoform Alpha-2"
}Increases activity of isoform Alpha
Evidence & references
- ECO:0000269 PubMed:11358809 ↗
Complete source annotation
{
"texts": [
{
"evidences": [
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "11358809"
}
],
"value": "Increases activity of isoform Alpha"
}
],
"commentType": "FUNCTION",
"molecule": "Isoform GR-P"
}More effective than isoform Alpha in transcriptional activation, but not repression activity
Evidence & references
- ECO:0000269 PubMed:11435610 ↗
- ECO:0000269 PubMed:15866175 ↗
Complete source annotation
{
"texts": [
{
"evidences": [
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "11435610"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "15866175"
}
],
"value": "More effective than isoform Alpha in transcriptional activation, but not repression activity"
}
],
"commentType": "FUNCTION",
"molecule": "Isoform Alpha-B"
}Has transcriptional activation activity
Evidence & references
- ECO:0000269 PubMed:20484466 ↗
Complete source annotation
{
"texts": [
{
"evidences": [
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "20484466"
}
],
"value": "Has transcriptional activation activity"
}
],
"commentType": "FUNCTION",
"molecule": "Isoform 10"
}Has transcriptional activation activity
Evidence & references
- ECO:0000269 PubMed:15866175 ↗
Complete source annotation
{
"texts": [
{
"evidences": [
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "15866175"
}
],
"value": "Has transcriptional activation activity"
}
],
"commentType": "FUNCTION",
"molecule": "Isoform Alpha-C1"
}Has transcriptional activation activity
Evidence & references
- ECO:0000269 PubMed:15866175 ↗
Complete source annotation
{
"texts": [
{
"evidences": [
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "15866175"
}
],
"value": "Has transcriptional activation activity"
}
],
"commentType": "FUNCTION",
"molecule": "Isoform Alpha-C2"
}Has highest transcriptional activation activity of all isoforms created by alternative initiation [39, 64]. Has transcriptional repression activity [61]. Mediates glucocorticoid-induced apoptosis [61, 64]
Evidence & references
- ECO:0000269 PubMed:15866175 ↗
- ECO:0000269 PubMed:23303127 ↗
- ECO:0000269 PubMed:23820903 ↗
Complete source annotation
{
"texts": [
{
"evidences": [
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "15866175"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "23303127"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "23820903"
}
],
"value": "Has highest transcriptional activation activity of all isoforms created by alternative initiation (PubMed:15866175, PubMed:23820903). Has transcriptional repression activity (PubMed:23303127). Mediates glucocorticoid-induced apoptosis (PubMed:23303127, PubMed:23820903)"
}
],
"commentType": "FUNCTION",
"molecule": "Isoform Alpha-C3"
}Has transcriptional activation activity
Evidence & references
- ECO:0000269 PubMed:15866175 ↗
Complete source annotation
{
"texts": [
{
"evidences": [
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "15866175"
}
],
"value": "Has transcriptional activation activity"
}
],
"commentType": "FUNCTION",
"molecule": "Isoform Alpha-D1"
}Has transcriptional activation activity
Evidence & references
- ECO:0000269 PubMed:15866175 ↗
Complete source annotation
{
"texts": [
{
"evidences": [
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "15866175"
}
],
"value": "Has transcriptional activation activity"
}
],
"commentType": "FUNCTION",
"molecule": "Isoform Alpha-D2"
}Has lowest transcriptional activation activity of all isoforms created by alternative initiation [39, 64]. Has transcriptional repression activity [61]
Evidence & references
- ECO:0000269 PubMed:15866175 ↗
- ECO:0000269 PubMed:23303127 ↗
- ECO:0000269 PubMed:23820903 ↗
Complete source annotation
{
"texts": [
{
"evidences": [
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "15866175"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "23303127"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "23820903"
}
],
"value": "Has lowest transcriptional activation activity of all isoforms created by alternative initiation (PubMed:15866175, PubMed:23820903). Has transcriptional repression activity (PubMed:23303127)"
}
],
"commentType": "FUNCTION",
"molecule": "Isoform Alpha-D3"
}Additional functional context
Isoform BetaHigh constitutive expression by neutrophils may provide a mechanism by which these cells escape glucocorticoid-induced cell death and up-regulation by pro-inflammatory cytokines such as IL8 further enhances their survival in the presence of glucocorticoids during inflammation
Evidence & references
- ECO:0000269 PubMed:11238589 ↗
Complete source annotation
{
"texts": [
{
"evidences": [
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "11238589"
}
],
"value": "High constitutive expression by neutrophils may provide a mechanism by which these cells escape glucocorticoid-induced cell death and up-regulation by pro-inflammatory cytokines such as IL8 further enhances their survival in the presence of glucocorticoids during inflammation"
}
],
"commentType": "MISCELLANEOUS",
"molecule": "Isoform Beta"
}Can up- or down-modulate aggregation and nuclear localization of expanded polyglutamine polypeptides derived from AR and HD through specific regulation of gene expression. Aggregation and nuclear localization of expanded polyglutamine proteins are regulated cellular processes that can be modulated by this receptor, a well-characterized transcriptional regulator
Evidence & references
- ECO:0000269 PubMed:10639135 ↗
Complete source annotation
{
"texts": [
{
"evidences": [
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "10639135"
}
],
"value": "Can up- or down-modulate aggregation and nuclear localization of expanded polyglutamine polypeptides derived from AR and HD through specific regulation of gene expression. Aggregation and nuclear localization of expanded polyglutamine proteins are regulated cellular processes that can be modulated by this receptor, a well-characterized transcriptional regulator"
}
],
"commentType": "MISCELLANEOUS"
}Predominant physiological form
Evidence & references
- ECO:0000269 PubMed:15866175 ↗
Complete source annotation
{
"texts": [
{
"evidences": [
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "15866175"
}
],
"value": "Predominant physiological form"
}
],
"commentType": "MISCELLANEOUS",
"molecule": "Isoform Alpha"
}Due to a partial intron retention
Evidence & references
- ECO:0000305
Complete source annotation
{
"texts": [
{
"evidences": [
{
"evidenceCode": "ECO:0000305"
}
],
"value": "Due to a partial intron retention"
}
],
"commentType": "MISCELLANEOUS",
"molecule": "Isoform Alpha-2"
}Due to a partial intron retention
Evidence & references
- ECO:0000305
Complete source annotation
{
"texts": [
{
"evidences": [
{
"evidenceCode": "ECO:0000305"
}
],
"value": "Due to a partial intron retention"
}
],
"commentType": "MISCELLANEOUS",
"molecule": "Isoform Beta-2"
}Lacks exons 5, 6 and 7. Found in glucocorticoid-resistant myeloma patients
Evidence & references
- ECO:0000269 PubMed:8358712 ↗
Complete source annotation
{
"texts": [
{
"evidences": [
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "8358712"
}
],
"value": "Lacks exons 5, 6 and 7. Found in glucocorticoid-resistant myeloma patients"
}
],
"commentType": "MISCELLANEOUS",
"molecule": "Isoform GR-A alpha"
}Lacks exons 5, 6 and 7
Evidence & references
- ECO:0000269 PubMed:8358712 ↗
Complete source annotation
{
"texts": [
{
"evidences": [
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "8358712"
}
],
"value": "Lacks exons 5, 6 and 7"
}
],
"commentType": "MISCELLANEOUS",
"molecule": "Isoform GR-A beta"
}Encoded by exons 2-7 plus several basepairs from the subsequent intron region. Lacks the ligand binding domain. Accounts for up to 10-20% of mRNAs
Evidence & references
- ECO:0000269 PubMed:8358712 ↗
Complete source annotation
{
"texts": [
{
"evidences": [
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "8358712"
}
],
"value": "Encoded by exons 2-7 plus several basepairs from the subsequent intron region. Lacks the ligand binding domain. Accounts for up to 10-20% of mRNAs"
}
],
"commentType": "MISCELLANEOUS",
"molecule": "Isoform GR-P"
}Produced by alternative initiation at Met-27 of isoform Alpha
Evidence & references
- ECO:0000305
Complete source annotation
{
"texts": [
{
"evidences": [
{
"evidenceCode": "ECO:0000305"
}
],
"value": "Produced by alternative initiation at Met-27 of isoform Alpha"
}
],
"commentType": "MISCELLANEOUS",
"molecule": "Isoform Alpha-B"
}Produced by alternative initiation at Met-27 of isoform Beta
Evidence & references
- ECO:0000269 PubMed:15866175 ↗
- ECO:0000305
Complete source annotation
{
"texts": [
{
"evidences": [
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "15866175"
},
{
"evidenceCode": "ECO:0000305"
}
],
"value": "Produced by alternative initiation at Met-27 of isoform Beta"
}
],
"commentType": "MISCELLANEOUS",
"molecule": "Isoform Beta-B"
}Produced by alternative initiation at Met-86 of isoform Alpha
Evidence & references
- ECO:0000269 PubMed:15866175 ↗
Complete source annotation
{
"texts": [
{
"evidences": [
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "15866175"
}
],
"value": "Produced by alternative initiation at Met-86 of isoform Alpha"
}
],
"commentType": "MISCELLANEOUS",
"molecule": "Isoform Alpha-C1"
}Produced by alternative initiation at Met-90 of isoform Alpha
Evidence & references
- ECO:0000269 PubMed:15866175 ↗
Complete source annotation
{
"texts": [
{
"evidences": [
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "15866175"
}
],
"value": "Produced by alternative initiation at Met-90 of isoform Alpha"
}
],
"commentType": "MISCELLANEOUS",
"molecule": "Isoform Alpha-C2"
}Produced by alternative initiation at Met-98 of isoform Alpha
Evidence & references
- ECO:0000269 PubMed:15866175 ↗
Complete source annotation
{
"texts": [
{
"evidences": [
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "15866175"
}
],
"value": "Produced by alternative initiation at Met-98 of isoform Alpha"
}
],
"commentType": "MISCELLANEOUS",
"molecule": "Isoform Alpha-C3"
}Produced by alternative initiation at Met-316 of isoform Alpha
Evidence & references
- ECO:0000269 PubMed:15866175 ↗
Complete source annotation
{
"texts": [
{
"evidences": [
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "15866175"
}
],
"value": "Produced by alternative initiation at Met-316 of isoform Alpha"
}
],
"commentType": "MISCELLANEOUS",
"molecule": "Isoform Alpha-D1"
}Produced by alternative initiation at Met-331 of isoform Alpha
Evidence & references
- ECO:0000269 PubMed:15866175 ↗
Complete source annotation
{
"texts": [
{
"evidences": [
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "15866175"
}
],
"value": "Produced by alternative initiation at Met-331 of isoform Alpha"
}
],
"commentType": "MISCELLANEOUS",
"molecule": "Isoform Alpha-D2"
}Produced by alternative initiation at Met-336 of isoform Alpha
Evidence & references
- ECO:0000269 PubMed:15866175 ↗
Complete source annotation
{
"texts": [
{
"evidences": [
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "15866175"
}
],
"value": "Produced by alternative initiation at Met-336 of isoform Alpha"
}
],
"commentType": "MISCELLANEOUS",
"molecule": "Isoform Alpha-D3"
}GO functions & biological processes
GO:0000977 · evidence & context
- ECO:0000314 PMID:1894621 ↗ IDA · NTNU_SB · 20191022qualifier: enables
GO:0000978 · evidence & context
- ECO:0000314 PMID:16728402 ↗ IDA · NTNU_SB · 20140331qualifier: enables
GO:0000981 · evidence & context
- ECO:0005556 GO_REF:0000113 ISA · NTNU_SB · 20190405qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "tfclass", "id": "2.1.1"}]}]
GO:0001046 · evidence & context
- ECO:0000314 PMID:17081986 ↗ IDA · CAFA · 20191205qualifier: enablesextensions: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q99576", "relation": "has_input"}]}]
GO:0001227 · evidence & context
- ECO:0000314 PMID:1894621 ↗ IDA · NTNU_SB · 20191022qualifier: enables
All recorded function and process assertions (53)
GO:0001228 · evidence & context
- ECO:0000314 PMID:16728402 ↗ IDA · NTNU_SB · 20140331qualifier: enables
GO:0001228 · evidence & context
- ECO:0000314 PMID:23823477 ↗ IDA · UniProt · 20220204qualifier: enablesextensions: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q8TAP4", "relation": "has_input"}]}]
GO:0001228 · evidence & context
- ECO:0000314 PMID:28139699 ↗ IDA · UniProt · 20221212qualifier: enablesextensions: [{"connectedXrefs": [{"db": "GO", "id": "0071385", "relation": "part_of"}, {"db": "GO", "id": "0005634", "relation": "occurs_in"}]}]
GO:0003677 · evidence & context
- ECO:0000501 GO_REF:0000120 IEA · UniProt · 20260727qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P06537"}]}, {"connectedXrefs": [{"db": "ensembl", "id": "ENSMUSP00000111229"}]}, {"connectedXrefs": [{"db": "InterPro", "id": "IPR001409"}]}]
GO:0003700 · evidence & context
- ECO:0000256 GO_REF:0000002 IEA · InterPro · 20260727qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "InterPro", "id": "IPR001628"}]}]
- ECO:0000304 PMID:10903900 ↗ TAS · PINC · 20030904qualifier: enables
- ECO:0000314 PMID:15769988 ↗ IDA · UniProt · 20141124qualifier: enables
- ECO:0000304 PMID:7769088 ↗ TAS · PINC · 20030904qualifier: enables
GO:0003707 · evidence & context
- ECO:0000256 GO_REF:0000117 IEA · UniProt · 20260727qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "ARBA", "id": "ARBA00089151"}]}]
GO:0004879 · evidence & context
- ECO:0000318 GO_REF:0000033 IBA · GO_Central · 20250904qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "FB", "id": "FBgn0264562"}]}, {"connectedXrefs": [{"db": "MGI", "id": "MGI:1346832"}]}, {"connectedXrefs": [{"db": "MGI", "id": "MGI:1352467"}]}, {"connectedXrefs": [{"db": "MGI", "id": "MGI:88064"}]}, {"connectedXrefs": [{"db": "MGI", "id": "MGI:95824"}]}, {"connectedXrefs": [{"db": "MGI", "id": "MGI:97567"}]}, {"connectedXrefs": [{"db": "PANTHER", "id": "PTN002377694"}]}, {"connectedXrefs": [{"db": "RGD", "id": "2147"}]}, {"connectedXrefs": [{"db": "RGD", "id": "2581"}]}, {"connectedXrefs": [{"db": "RGD", "id": "2582"}]}, {"connectedXrefs": [{"db": "RGD", "id": "3094"}]}, {"connectedXrefs": [{"db": "RGD", "id": "3317"}]}, {"connectedXrefs": [{"db": "UniProtKB", "id": "P03372"}]}, {"connectedXrefs": [{"db": "UniProtKB", "id": "P04150"}]}, {"connectedXrefs": [{"db": "UniProtKB", "id": "P06212"}]}, {"connectedXrefs": [{"db": "UniProtKB", "id": "P06401"}]}, {"connectedXrefs": [{"db": "UniProtKB", "id": "P10275"}]}, {"connectedXrefs": [{"db": "UniProtKB", "id": "Q92731"}]}, {"connectedXrefs": [{"db": "ZFIN", "id": "ZDB-GENE-020806-5"}]}, {"connectedXrefs": [{"db": "ZFIN", "id": "ZDB-GENE-030116-1"}]}, {"connectedXrefs": [{"db": "ZFIN", "id": "ZDB-GENE-030116-2"}]}, {"connectedXrefs": [{"db": "ZFIN", "id": "ZDB-GENE-050522-503"}]}, {"connectedXrefs": [{"db": "ZFIN", "id": "ZDB-GENE-060131-1"}]}, {"connectedXrefs": [{"db": "ZFIN", "id": "ZDB-GENE-060531-23"}]}, {"connectedXrefs": [{"db": "ZFIN", "id": "ZDB-GENE-990415-214"}]}]
- ECO:0000314 PMID:17635946 ↗ IDA · UniProt · 20180525qualifier: enables
GO:0004883 · evidence & context
- ECO:0000501 GO_REF:0000120 IEA · UniProt · 20260727qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P06537"}]}, {"connectedXrefs": [{"db": "ensembl", "id": "ENSMUSP00000111229"}]}, {"connectedXrefs": [{"db": "InterPro", "id": "IPR001409"}]}]
- ECO:0000304 PMID:8621628 ↗ TAS · PINC · 20030904qualifier: enables
GO:0005496 · evidence & context
- ECO:0000256 GO_REF:0000002 IEA · InterPro · 20260727qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "InterPro", "id": "IPR001409"}]}]
- ECO:0000314 PMID:15769988 ↗ IDA · UniProt · 20141124qualifier: enables
GO:0005515 · evidence & context
- ECO:0000353 PMID:10364267 ↗ IPI · UniProt · 20050927qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P48552"}]}]
- ECO:0000353 PMID:11266503 ↗ IPI · UniProt · 20050927qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P48552"}]}]
- ECO:0000353 PMID:12552091 ↗ IPI · BHF-UCL · 20081209qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P51692"}]}]
- ECO:0000353 PMID:12773562 ↗ IPI · UniProt · 20050927qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P48552"}]}]
- ECO:0000353 PMID:12902338 ↗ IPI · CAFA · 20160822qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P84022"}]}]
- ECO:0000353 PMID:15591535 ↗ IPI · UniProt · 20150619qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P22829"}]}]
- ECO:0000353 PMID:15591535 ↗ IPI · UniProt · 20150619qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P51179"}]}]
- ECO:0000353 PMID:15591535 ↗ IPI · UniProt · 20150619qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q06219"}]}]
- ECO:0000353 PMID:15769988 ↗ IPI · UniProt · 20141124qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q9Y3R0"}]}]
- ECO:0000353 PMID:15941832 ↗ IPI · HGNC-UCL · 20050627qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "O94992"}]}]
- ECO:0000353 PMID:16606617 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P59598"}]}]
- ECO:0000353 PMID:16619302 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q62667"}]}]
- ECO:0000353 PMID:16888650 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P01730"}]}]
- ECO:0000353 PMID:16888650 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P06239"}]}]
- ECO:0000353 PMID:17003263 ↗ IPI · UniProt · 20100624qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P68036"}]}]
- ECO:0000353 PMID:17635946 ↗ IPI · UniProt · 20141124qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q9Y3R0"}]}]
- ECO:0000353 PMID:19141540 ↗ IPI · UniProt · 20140223qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "O08785"}]}]
- ECO:0000353 PMID:19841061 ↗ IPI · DisProt · 20230112qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P12931"}, {"db": "UniProtKB", "id": "Q92793"}]}]
- ECO:0000353 PMID:20195357 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P07900"}]}]
- ECO:0000353 PMID:20195357 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P82094"}]}]
- ECO:0000353 PMID:20195357 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q6ZU52"}]}]
- ECO:0000353 PMID:20211142 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P28702"}]}]
- ECO:0000353 PMID:21980503 ↗ IPI · UniProt · 20140223qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "O15516"}]}]
- ECO:0000353 PMID:22170608 ↗ IPI · UniProt · 20140430qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P97784"}]}]
- ECO:0000353 PMID:22170608 ↗ IPI · UniProt · 20140430qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q9R194"}]}]
- ECO:0000353 PMID:24291004 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P31749"}]}]
- ECO:0000353 PMID:24658140 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P00533"}]}]
- ECO:0000353 PMID:24949977 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P07900"}]}]
- ECO:0000353 PMID:27353360 ↗ IPI · UniProt · 20161004qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q8TF40"}]}]
- ECO:0000353 PMID:27353360 ↗ IPI · UniProt · 20161004qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q9P278"}]}]
- ECO:0000353 PMID:31467278 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P07900"}]}]
- ECO:0000353 PMID:31980649 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P00533"}]}]
- ECO:0000353 PMID:32814053 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "O95416"}]}]
- ECO:0000353 PMID:32814053 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q14141"}]}]
- ECO:0000353 PMID:9079630 ↗ IPI · UniProt · 20051118qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q04917"}]}]
GO:0005515 · evidence & context
- ECO:0000353 PMID:17978169 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P41235"}]}]extensions: [{"connectedXrefs": [{"db": "GO", "id": "0005634", "relation": "occurs_in"}]}]
GO:0008270 · evidence & context
- ECO:0000256 GO_REF:0000002 IEA · InterPro · 20260727qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "InterPro", "id": "IPR001628"}]}, {"connectedXrefs": [{"db": "InterPro", "id": "IPR013088"}]}]
GO:0017025 · evidence & context
- ECO:0000353 PMID:19841061 ↗ IPI · DisProt · 20230112qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P20226"}]}]
GO:0019901 · evidence & context
- ECO:0000501 GO_REF:0000120 IEA · UniProt · 20260724qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "ARBA", "id": "ARBA00028598"}]}, {"connectedXrefs": [{"db": "UniProtKB", "id": "P06537"}]}, {"connectedXrefs": [{"db": "ensembl", "id": "ENSMUSP00000111229"}]}]
- ECO:0000353 PMID:20371704 ↗ IPI · ARUK-UCL · 20171027qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P49840"}]}]
GO:0034056 · evidence & context
- ECO:0000318 GO_REF:0000033 IBA · GO_Central · 20221130qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "MGI", "id": "MGI:1347056"}]}, {"connectedXrefs": [{"db": "PANTHER", "id": "PTN001182563"}]}, {"connectedXrefs": [{"db": "RGD", "id": "2582"}]}, {"connectedXrefs": [{"db": "UniProtKB", "id": "P03372"}]}, {"connectedXrefs": [{"db": "UniProtKB", "id": "Q92731"}]}]
GO:0042802 · evidence & context
- ECO:0000265 GO_REF:0000107 IEA · Ensembl · 20260724qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P06537"}]}, {"connectedXrefs": [{"db": "ensembl", "id": "ENSMUSP00000111229"}]}]
GO:0043565 · evidence & context
- ECO:0000501 GO_REF:0000120 IEA · UniProt · 20260727qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P06537"}]}, {"connectedXrefs": [{"db": "ensembl", "id": "ENSMUSP00000111229"}]}, {"connectedXrefs": [{"db": "InterPro", "id": "IPR001628"}]}]
GO:0051879 · evidence & context
- ECO:0000353 PMID:26593036 ↗ IPI · UniProt · 20170317qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q18688"}]}]
GO:1990239 · evidence & context
- ECO:0000314 PMID:17635946 ↗ IDA · UniProt · 20141124qualifier: enables
GO:1990837 · evidence & context
- ECO:0000256 GO_REF:0000117 IEA · UniProt · 20260727qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "ARBA", "id": "ARBA00028376"}]}]
- ECO:0000314 PMID:28473536 ↗ IDA · ARUK-UCL · 20200608qualifier: enables
GO:1990841 · evidence & context
- ECO:0000265 GO_REF:0000107 IEA · Ensembl · 20260724qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P06537"}]}, {"connectedXrefs": [{"db": "ensembl", "id": "ENSMUSP00000111229"}]}]
GO:0000122 · evidence & context
- ECO:0000315 PMID:12902338 ↗ IMP · CAFA · 20160822qualifier: involved_in
- ECO:0000314 PMID:1894621 ↗ IDA · NTNU_SB · 20191023qualifier: involved_in
GO:0006355 · evidence & context
- ECO:0000256 GO_REF:0000002 IEA · InterPro · 20260727qualifier: involved_inwithFrom: [{"connectedXrefs": [{"db": "InterPro", "id": "IPR001409"}]}, {"connectedXrefs": [{"db": "InterPro", "id": "IPR001628"}]}, {"connectedXrefs": [{"db": "InterPro", "id": "IPR013088"}]}]
- ECO:0000314 PMID:19141540 ↗ IDA · UniProt · 20140223qualifier: involved_in
GO:0006355 · evidence & context
- ECO:0000314 PMID:17081986 ↗ IDA · CAFA · 20200501qualifier: involved_inextensions: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q99576", "relation": "has_input"}]}, {"connectedXrefs": [{"db": "UniProtKB", "id": "O60779", "relation": "has_input"}]}]
GO:0006357 · evidence & context
- ECO:0000318 GO_REF:0000033 IBA · GO_Central · 20241121qualifier: involved_inwithFrom: [{"connectedXrefs": [{"db": "FB", "id": "FBgn0035849"}]}, {"connectedXrefs": [{"db": "MGI", "id": "MGI:1346831"}]}, {"connectedXrefs": [{"db": "MGI", "id": "MGI:1346832"}]}, {"connectedXrefs": [{"db": "MGI", "id": "MGI:1347056"}]}, {"connectedXrefs": [{"db": "MGI", "id": "MGI:1352459"}]}, {"connectedXrefs": [{"db": "MGI", "id": "MGI:1352467"}]}, {"connectedXrefs": [{"db": "MGI", "id": "MGI:88064"}]}, {"connectedXrefs": [{"db": "PANTHER", "id": "PTN001182563"}]}, {"connectedXrefs": [{"db": "RGD", "id": "2582"}]}, {"connectedXrefs": [{"db": "RGD", "id": "2741"}]}, {"connectedXrefs": [{"db": "RGD", "id": "3094"}]}, {"connectedXrefs": [{"db": "UniProtKB", "id": "P03372"}]}, {"connectedXrefs": [{"db": "UniProtKB", "id": "P04150"}]}, {"connectedXrefs": [{"db": "UniProtKB", "id": "P06401"}]}, {"connectedXrefs": [{"db": "UniProtKB", "id": "P10275"}]}, {"connectedXrefs": [{"db": "UniProtKB", "id": "Q92731"}]}]
GO:0007165 · evidence & context
- ECO:0000304 PMID:7769088 ↗ TAS · PINC · 20030904qualifier: involved_in
GO:0014004 · evidence & context
- ECO:0000265 GO_REF:0000107 IEA · Ensembl · 20260724qualifier: involved_inwithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P06537"}]}, {"connectedXrefs": [{"db": "ensembl", "id": "ENSMUSP00000111229"}]}]
GO:0030518 · evidence & context
- ECO:0000318 GO_REF:0000033 IBA · GO_Central · 20240802qualifier: involved_inwithFrom: [{"connectedXrefs": [{"db": "MGI", "id": "MGI:95824"}]}, {"connectedXrefs": [{"db": "PANTHER", "id": "PTN002786985"}]}, {"connectedXrefs": [{"db": "RGD", "id": "2741"}]}]
GO:0031958 · evidence & context
- ECO:0000256 GO_REF:0000117 IEA · UniProt · 20260727qualifier: involved_inwithFrom: [{"connectedXrefs": [{"db": "ARBA", "id": "ARBA00086690"}]}]
GO:0035249 · evidence & context
- ECO:0000265 GO_REF:0000107 IEA · Ensembl · 20260724qualifier: involved_inwithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P06537"}]}, {"connectedXrefs": [{"db": "ensembl", "id": "ENSMUSP00000111229"}]}]
GO:0042921 · evidence & context
- ECO:0000256 GO_REF:0000002 IEA · InterPro · 20260727qualifier: involved_inwithFrom: [{"connectedXrefs": [{"db": "InterPro", "id": "IPR001409"}]}]
GO:0045892 · evidence & context
- ECO:0000314 PMID:1894621 ↗ IDA · UniProt · 20191022qualifier: involved_in
GO:0045893 · evidence & context
- ECO:0000256 GO_REF:0000117 IEA · UniProt · 20260727qualifier: involved_inwithFrom: [{"connectedXrefs": [{"db": "ARBA", "id": "ARBA00029082"}]}]
GO:0045944 · evidence & context
- ECO:0000314 PMID:15769988 ↗ IDA · UniProt · 20141124qualifier: involved_in
- ECO:0000315 PMID:9353307 ↗ IMP · UniProt · 20170821qualifier: involved_in
GO:0045944 · evidence & context
- ECO:0000314 PMID:16728402 ↗ IDA · NTNU_SB · 20140323qualifier: involved_inextensions: [{"connectedXrefs": [{"db": "NCBI_Gene", "id": "4128", "relation": "has_input"}]}]
GO:0045944 · evidence & context
- ECO:0000314 PMID:23823477 ↗ IDA · UniProt · 20140915qualifier: involved_inextensions: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q8TAP4", "relation": "has_input"}]}]
GO:0048708 · evidence & context
- ECO:0000265 GO_REF:0000107 IEA · Ensembl · 20260724qualifier: involved_inwithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P06537"}]}, {"connectedXrefs": [{"db": "ensembl", "id": "ENSMUSP00000111229"}]}]
GO:0051384 · evidence & context
- ECO:0000256 GO_REF:0000117 IEA · UniProt · 20260727qualifier: involved_inwithFrom: [{"connectedXrefs": [{"db": "ARBA", "id": "ARBA00089100"}]}]
GO:0061744 · evidence & context
- ECO:0000265 GO_REF:0000107 IEA · Ensembl · 20260724qualifier: involved_inwithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P06537"}]}, {"connectedXrefs": [{"db": "ensembl", "id": "ENSMUSP00000111229"}]}]
GO:0071383 · evidence & context
- ECO:0000314 PMID:15769988 ↗ IDA · UniProt · 20141124qualifier: involved_in
- ECO:0000314 PMID:17635946 ↗ IDA · UniProt · 20141124qualifier: involved_in
GO:0071385 · evidence & context
- ECO:0000314 PMID:28139699 ↗ IDA · UniProt · 20221212qualifier: involved_in
- ECO:0000314 PMID:9353307 ↗ IDA · UniProt · 20170821qualifier: involved_in
GO:0071549 · evidence & context
- ECO:0000315 PMID:12902338 ↗ IMP · CAFA · 20160822qualifier: involved_in
GO:0071560 · evidence & context
- ECO:0000314 PMID:12902338 ↗ IDA · CAFA · 20160822qualifier: involved_in
GO:0097049 · evidence & context
- ECO:0000265 GO_REF:0000107 IEA · Ensembl · 20260724qualifier: involved_inwithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P06537"}]}, {"connectedXrefs": [{"db": "ensembl", "id": "ENSMUSP00000111229"}]}]
GO:0150076 · evidence & context
- ECO:0000265 GO_REF:0000107 IEA · Ensembl · 20260724qualifier: involved_inwithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P06537"}]}, {"connectedXrefs": [{"db": "ensembl", "id": "ENSMUSP00000111229"}]}]
GO:1901654 · evidence & context
- ECO:0000256 GO_REF:0000117 IEA · UniProt · 20260727qualifier: involved_inwithFrom: [{"connectedXrefs": [{"db": "ARBA", "id": "ARBA00090656"}]}]
GO:1902895 · evidence & context
- ECO:0000265 GO_REF:0000107 IEA · Ensembl · 20260724qualifier: involved_inwithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P06537"}]}, {"connectedXrefs": [{"db": "ensembl", "id": "ENSMUSP00000111229"}]}]
GO:1902895 · evidence & context
- ECO:0000314 PMID:27334923 ↗ IDA · ARUK-UCL · 20210108qualifier: involved_inextensions: [{"connectedXrefs": [{"db": "RNAcentral", "id": "URS00006BADF6_9606", "relation": "has_input"}]}]
Names & Taxonomy
- Recommended name
- Glucocorticoid receptor
- Gene
- NR3C1
- Accession / entry
- P04150 · GCR_HUMAN
- Species
- Homo sapiens · NCBI 9606
- Recorded aliases
- GRL · Nuclear receptor subfamily 3 group C member 1
Full taxonomy & recorded names
Eukaryota → Metazoa → Chordata → Craniata → Vertebrata → Euteleostomi → Mammalia → Eutheria → Euarchontoglires → Primates → Haplorrhini → Catarrhini → Hominidae → Homo
{
"names": {
"recommendedName": {
"fullName": {
"value": "Glucocorticoid receptor"
},
"shortNames": [
{
"value": "GR"
}
]
},
"alternativeNames": [
{
"fullName": {
"value": "Nuclear receptor subfamily 3 group C member 1"
}
}
]
},
"genes": [
{
"geneName": {
"evidences": [
{
"evidenceCode": "ECO:0000312",
"source": "HGNC",
"id": "HGNC:7978"
}
],
"value": "NR3C1"
},
"synonyms": [
{
"value": "GRL"
}
]
}
]
}Subcellular Location
UniProt locations and GO cellular-component assertions. Relations and contexts remain distinct; “part of” is not automatically a residence claim.
Isoform Alpha
After ligand activation, translocates from the cytoplasm to the nucleus [104]. The hormone-occupied receptor undergoes rapid exchange between chromatin and the nucleoplasmic compartment (By similarity). In the presence of NR1D1 shows a time-dependent subcellular localization, localizing to the cytoplasm at ZT8 and to the nucleus at ZT20 (By similarity). Lacks this diurnal pattern of localization in the absence of NR1D1, localizing to both nucleus and the cytoplasm at ZT8 and ZT20 (By similarity). Upon dexamethasone binding associates with the glucocorticoid response elements of target genes (By similarity)
Evidence & references
- ECO:0000269 PubMed:15769988 ↗
- ECO:0000269 PubMed:17635946 ↗
- ECO:0000269 PubMed:18838540 ↗
- ECO:0000269 PubMed:27120390 ↗
- ECO:0000269 PubMed:30698747 ↗
- ECO:0000269 PubMed:8621628 ↗
Isoform Alpha
After ligand activation, translocates from the cytoplasm to the nucleus [104]. The hormone-occupied receptor undergoes rapid exchange between chromatin and the nucleoplasmic compartment (By similarity). In the presence of NR1D1 shows a time-dependent subcellular localization, localizing to the cytoplasm at ZT8 and to the nucleus at ZT20 (By similarity). Lacks this diurnal pattern of localization in the absence of NR1D1, localizing to both nucleus and the cytoplasm at ZT8 and ZT20 (By similarity). Upon dexamethasone binding associates with the glucocorticoid response elements of target genes (By similarity)
Evidence & references
- ECO:0000269 PubMed:15769988 ↗
- ECO:0000269 PubMed:17635946 ↗
- ECO:0000269 PubMed:18838540 ↗
- ECO:0000269 PubMed:27120390 ↗
- ECO:0000269 PubMed:30698747 ↗
- ECO:0000269 PubMed:8621628 ↗
Isoform Alpha
After ligand activation, translocates from the cytoplasm to the nucleus [104]. The hormone-occupied receptor undergoes rapid exchange between chromatin and the nucleoplasmic compartment (By similarity). In the presence of NR1D1 shows a time-dependent subcellular localization, localizing to the cytoplasm at ZT8 and to the nucleus at ZT20 (By similarity). Lacks this diurnal pattern of localization in the absence of NR1D1, localizing to both nucleus and the cytoplasm at ZT8 and ZT20 (By similarity). Upon dexamethasone binding associates with the glucocorticoid response elements of target genes (By similarity)
Evidence & references
- ECO:0000269 PubMed:21664385 ↗
Isoform Alpha
After ligand activation, translocates from the cytoplasm to the nucleus [104]. The hormone-occupied receptor undergoes rapid exchange between chromatin and the nucleoplasmic compartment (By similarity). In the presence of NR1D1 shows a time-dependent subcellular localization, localizing to the cytoplasm at ZT8 and to the nucleus at ZT20 (By similarity). Lacks this diurnal pattern of localization in the absence of NR1D1, localizing to both nucleus and the cytoplasm at ZT8 and ZT20 (By similarity). Upon dexamethasone binding associates with the glucocorticoid response elements of target genes (By similarity)
Evidence & references
- ECO:0000269 PubMed:25847991 ↗
Isoform Alpha
After ligand activation, translocates from the cytoplasm to the nucleus [104]. The hormone-occupied receptor undergoes rapid exchange between chromatin and the nucleoplasmic compartment (By similarity). In the presence of NR1D1 shows a time-dependent subcellular localization, localizing to the cytoplasm at ZT8 and to the nucleus at ZT20 (By similarity). Lacks this diurnal pattern of localization in the absence of NR1D1, localizing to both nucleus and the cytoplasm at ZT8 and ZT20 (By similarity). Upon dexamethasone binding associates with the glucocorticoid response elements of target genes (By similarity)
Evidence & references
- ECO:0000269 PubMed:25847991 ↗
Isoform Alpha
After ligand activation, translocates from the cytoplasm to the nucleus [104]. The hormone-occupied receptor undergoes rapid exchange between chromatin and the nucleoplasmic compartment (By similarity). In the presence of NR1D1 shows a time-dependent subcellular localization, localizing to the cytoplasm at ZT8 and to the nucleus at ZT20 (By similarity). Lacks this diurnal pattern of localization in the absence of NR1D1, localizing to both nucleus and the cytoplasm at ZT8 and ZT20 (By similarity). Upon dexamethasone binding associates with the glucocorticoid response elements of target genes (By similarity)
Evidence & references
- ECO:0000250 UniProtKB:P06537
Isoform Alpha
After ligand activation, translocates from the cytoplasm to the nucleus [104]. The hormone-occupied receptor undergoes rapid exchange between chromatin and the nucleoplasmic compartment (By similarity). In the presence of NR1D1 shows a time-dependent subcellular localization, localizing to the cytoplasm at ZT8 and to the nucleus at ZT20 (By similarity). Lacks this diurnal pattern of localization in the absence of NR1D1, localizing to both nucleus and the cytoplasm at ZT8 and ZT20 (By similarity). Upon dexamethasone binding associates with the glucocorticoid response elements of target genes (By similarity)
Evidence & references
- ECO:0000250 UniProtKB:P06537
Isoform Beta
Expressed predominantly in the nucleus with some expression also detected in the cytoplasm
Evidence & references
- ECO:0000269 PubMed:19248771 ↗
- ECO:0000269 PubMed:26711253 ↗
- ECO:0000269 PubMed:8621628 ↗
All recorded location assertions (27)
Isoform Beta
Expressed predominantly in the nucleus with some expression also detected in the cytoplasm
Evidence & references
- ECO:0000269 PubMed:19248771 ↗
- ECO:0000269 PubMed:26711253 ↗
Isoform Alpha-B
After ligand activation, translocates from the cytoplasm to the nucleus
Evidence & references
- ECO:0000269 PubMed:15866175 ↗
Isoform Alpha-B
After ligand activation, translocates from the cytoplasm to the nucleus
Evidence & references
- ECO:0000269 PubMed:15866175 ↗
Evidence & references
- ECO:0000318 GO_REF:0000033 IBA · GO_Central · 20250413qualifier: is_active_inwithFrom: [{"connectedXrefs": [{"db": "PANTHER", "id": "PTN002377694"}]}, {"connectedXrefs": [{"db": "RGD", "id": "2741"}]}, {"connectedXrefs": [{"db": "UniProtKB", "id": "P03372"}]}, {"connectedXrefs": [{"db": "UniProtKB", "id": "P06401"}]}, {"connectedXrefs": [{"db": "UniProtKB", "id": "P07812"}]}, {"connectedXrefs": [{"db": "UniProtKB", "id": "P10275"}]}]
Evidence & references
- ECO:0000318 GO_REF:0000033 IBA · GO_Central · 20260601qualifier: is_active_inwithFrom: [{"connectedXrefs": [{"db": "FB", "id": "FBgn0264562"}]}, {"connectedXrefs": [{"db": "MGI", "id": "MGI:109392"}]}, {"connectedXrefs": [{"db": "MGI", "id": "MGI:1346831"}]}, {"connectedXrefs": [{"db": "MGI", "id": "MGI:1346832"}]}, {"connectedXrefs": [{"db": "MGI", "id": "MGI:1352467"}]}, {"connectedXrefs": [{"db": "MGI", "id": "MGI:88064"}]}, {"connectedXrefs": [{"db": "MGI", "id": "MGI:95824"}]}, {"connectedXrefs": [{"db": "PANTHER", "id": "PTN001182563"}]}, {"connectedXrefs": [{"db": "RGD", "id": "2147"}]}, {"connectedXrefs": [{"db": "RGD", "id": "2581"}]}, {"connectedXrefs": [{"db": "RGD", "id": "3094"}]}, {"connectedXrefs": [{"db": "UniProtKB", "id": "A0A1D5PRD7"}]}, {"connectedXrefs": [{"db": "UniProtKB", "id": "O95718"}]}, {"connectedXrefs": [{"db": "UniProtKB", "id": "P03372"}]}, {"connectedXrefs": [{"db": "UniProtKB", "id": "P04150"}]}, {"connectedXrefs": [{"db": "UniProtKB", "id": "P06212"}]}, {"connectedXrefs": [{"db": "UniProtKB", "id": "P07812"}]}, {"connectedXrefs": [{"db": "UniProtKB", "id": "P08235"}]}, {"connectedXrefs": [{"db": "UniProtKB", "id": "P10275"}]}, {"connectedXrefs": [{"db": "UniProtKB", "id": "P11474"}]}, {"connectedXrefs": [{"db": "UniProtKB", "id": "P49884"}]}, {"connectedXrefs": [{"db": "UniProtKB", "id": "P70033"}]}, {"connectedXrefs": [{"db": "UniProtKB", "id": "Q15406"}]}, {"connectedXrefs": [{"db": "UniProtKB", "id": "Q92731"}]}, {"connectedXrefs": [{"db": "ZFIN", "id": "ZDB-GENE-050522-503"}]}]
- ECO:0000314 PMID:28139699 ↗ IDA · UniProt · 20221212qualifier: is_active_in
Evidence & references
- ECO:0005556 GO_REF:0000113 ISA · NTNU_SB · 20190405qualifier: located_inwithFrom: [{"connectedXrefs": [{"db": "tfclass", "id": "2.1.1"}]}]
Evidence & references
- ECO:0000501 GO_REF:0000120 IEA · UniProt · 20260727qualifier: located_inwithFrom: [{"connectedXrefs": [{"db": "ARBA", "id": "ARBA00026330"}]}, {"connectedXrefs": [{"db": "UniProtKB", "id": "P06537"}]}, {"connectedXrefs": [{"db": "ensembl", "id": "ENSMUSP00000111229"}]}, {"connectedXrefs": [{"db": "InterPro", "id": "IPR001409"}]}, {"connectedXrefs": [{"db": "UniProtKB-SubCell", "id": "SL-0191"}]}]
- ECO:0000314 PMID:15769988 ↗ IDA · UniProt · 20141124qualifier: located_in
- ECO:0000314 PMID:17635946 ↗ IDA · UniProt · 20141124qualifier: located_in
- ECO:0000305 PMID:1894621 ↗ IC · UniProt · 20191022qualifier: located_inwithFrom: [{"connectedXrefs": [{"db": "GO", "id": "0045892"}]}]
- ECO:0000314 PMID:22022502 ↗ IDA · UniProt · 20161011qualifier: located_in
- ECO:0000314 PMID:23878391 ↗ IDA · MGI · 20140926qualifier: located_in
- ECO:0000269 PMID:27120390 ↗ EXP · UniProt · 20240916qualifier: located_in
- ECO:0000269 PMID:30698747 ↗ EXP · UniProt · 20240916qualifier: located_in
- ECO:0000269 PMID:8621628 ↗ EXP · UniProt · 20240916qualifier: located_in
- ECO:0000314 PMID:9353307 ↗ IDA · UniProt · 20170821qualifier: located_in
- ECO:0000304 PMID:9873044 ↗ TAS · PINC · 20030904qualifier: located_in
Evidence & references
- ECO:0007322 GO_REF:0000044 IEA · UniProt · 20260727qualifier: located_inwithFrom: [{"connectedXrefs": [{"db": "UniProtKB-SubCell", "id": "SL-0190"}]}]
- ECO:0000314 GO_REF:0000052 IDA · HPA · 20251115qualifier: located_in
- ECO:0000304 Reactome:R-HSA-376419 TAS · Reactome · 20130226qualifier: located_in
- ECO:0000304 Reactome:R-HSA-382096 TAS · Reactome · 20130226qualifier: located_in
- ECO:0000304 Reactome:R-HSA-4341025 TAS · Reactome · 20160716qualifier: located_in
- ECO:0000304 Reactome:R-HSA-5618080 TAS · Reactome · 20130516qualifier: located_in
- ECO:0000304 Reactome:R-HSA-5618093 TAS · Reactome · 20130516qualifier: located_in
- ECO:0000304 Reactome:R-HSA-8856930 TAS · Reactome · 20130516qualifier: located_in
Evidence & references
- ECO:0000250 GO_REF:0000024 ISS · UniProt · 20240916qualifier: located_inwithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P06537"}]}]
- ECO:0007322 GO_REF:0000044 IEA · UniProt · 20260727qualifier: located_inwithFrom: [{"connectedXrefs": [{"db": "UniProtKB-SubCell", "id": "SL-0468"}]}]
Evidence & references
- ECO:0000501 GO_REF:0000120 IEA · UniProt · 20260727qualifier: located_inwithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P06537"}]}, {"connectedXrefs": [{"db": "ensembl", "id": "ENSMUSP00000111229"}]}, {"connectedXrefs": [{"db": "UniProtKB-SubCell", "id": "SL-0086"}]}]
- ECO:0000314 PMID:15769988 ↗ IDA · UniProt · 20141124qualifier: located_in
- ECO:0000314 PMID:17635946 ↗ IDA · UniProt · 20141124qualifier: located_in
- ECO:0000314 PMID:22022502 ↗ IDA · UniProt · 20161011qualifier: located_in
- ECO:0000269 PMID:27120390 ↗ EXP · UniProt · 20240916qualifier: located_in
- ECO:0000269 PMID:30698747 ↗ EXP · UniProt · 20240916qualifier: located_in
- ECO:0000269 PMID:8621628 ↗ EXP · UniProt · 20240916qualifier: located_in
- ECO:0000304 PMID:9873044 ↗ TAS · PINC · 20030904qualifier: located_in
Evidence & references
- ECO:0007322 GO_REF:0000044 IEA · UniProt · 20260727qualifier: located_inwithFrom: [{"connectedXrefs": [{"db": "UniProtKB-SubCell", "id": "SL-0173"}]}]
- ECO:0000314 GO_REF:0000052 IDA · HPA · 20251115qualifier: located_in
Evidence & references
- ECO:0000304 PMID:10887960 ↗ TAS · PINC · 20030904qualifier: located_in
Evidence & references
- ECO:0007322 GO_REF:0000044 IEA · UniProt · 20260727qualifier: located_inwithFrom: [{"connectedXrefs": [{"db": "UniProtKB-SubCell", "id": "SL-0048"}]}]
Evidence & references
- ECO:0007322 GO_REF:0000044 IEA · UniProt · 20260727qualifier: located_inwithFrom: [{"connectedXrefs": [{"db": "UniProtKB-SubCell", "id": "SL-0251"}]}]
Evidence & references
- ECO:0000314 GO_REF:0000052 IDA · HPA · 20251115qualifier: located_in
- ECO:0000501 GO_REF:0000120 IEA · UniProt · 20260724qualifier: located_inwithFrom: [{"connectedXrefs": [{"db": "ARBA", "id": "ARBA00029243"}]}, {"connectedXrefs": [{"db": "UniProtKB", "id": "P06537"}]}, {"connectedXrefs": [{"db": "ensembl", "id": "ENSMUSP00000111229"}]}]
- ECO:0000304 Reactome:R-HSA-5618080 TAS · Reactome · 20160716qualifier: located_in
- ECO:0000304 Reactome:R-HSA-9678925 TAS · Reactome · 20160716qualifier: located_in
- ECO:0000304 Reactome:R-HSA-9690534 TAS · Reactome · 20160716qualifier: located_in
Evidence & references
- ECO:0000265 GO_REF:0000107 IEA · Ensembl · 20260724qualifier: located_inwithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P06537"}]}, {"connectedXrefs": [{"db": "ensembl", "id": "ENSMUSP00000111229"}]}]
Evidence & references
- ECO:0000314 PMID:9353307 ↗ IDA · UniProt · 20170821qualifier: located_in
Evidence & references
- ECO:0000366 GO_REF:0000108 IEA · GOC · 20260727qualifier: located_inwithFrom: [{"connectedXrefs": [{"db": "GO", "id": "0035249"}]}]
Evidence & references
- ECO:0000314 PMID:26593036 ↗ IDA · UniProt · 20161017qualifier: part_of
Membrane topology 0
No annotation is recorded in this UniProt entry.
Disease & Variants
Source annotations; a recorded variant is not automatically a clinical classification.
Glucocorticoid resistance, generalized GCCR
An autosomal dominant disease characterized by increased plasma cortisol concentration and high urinary free cortisol, resistance to adrenal suppression by dexamethasone, and the absence of Cushing syndrome typical signs. Clinical features include hypoglycemia, hypertension, metabolic alkalosis, chronic fatigue and profound anxiety.
Evidence & references
- ECO:0000269 PubMed:11589680 ↗
- ECO:0000269 PubMed:11701741 ↗
- ECO:0000269 PubMed:12050230 ↗
- ECO:0000269 PubMed:15769988 ↗
- ECO:0000269 PubMed:1704018 ↗
- ECO:0000269 PubMed:17635946 ↗
- ECO:0000269 PubMed:20335448 ↗
- ECO:0000269 PubMed:21362280 ↗
- ECO:0000269 PubMed:23426617 ↗
- ECO:0000269 PubMed:24483153 ↗
- ECO:0000269 PubMed:26031419 ↗
- ECO:0000269 PubMed:26541474 ↗
- ECO:0000269 PubMed:27120390 ↗
- ECO:0000269 PubMed:7683692 ↗
The disease is caused by variants affecting the gene represented in this entry
Evidence & references
No separate evidence record is supplied for this statement.
Complete source annotation
{
"commentType": "DISEASE",
"disease": {
"diseaseId": "Glucocorticoid resistance, generalized",
"diseaseAccession": "DI-04226",
"acronym": "GCCR",
"description": "An autosomal dominant disease characterized by increased plasma cortisol concentration and high urinary free cortisol, resistance to adrenal suppression by dexamethasone, and the absence of Cushing syndrome typical signs. Clinical features include hypoglycemia, hypertension, metabolic alkalosis, chronic fatigue and profound anxiety.",
"diseaseCrossReference": {
"database": "MIM",
"id": "615962"
},
"evidences": [
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "11589680"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "11701741"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "12050230"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "15769988"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "1704018"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "17635946"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "20335448"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "21362280"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "23426617"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "24483153"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "26031419"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "26541474"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "27120390"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "7683692"
}
]
},
"note": {
"texts": [
{
"value": "The disease is caused by variants affecting the gene represented in this entry"
}
]
}
}Polymorphism notes
Carriers of the 22-Glu-Lys-23 allele are relatively more resistant to the effects of GCs with respect to the sensitivity of the adrenal feedback mechanism than non-carriers, resulting in a better metabolic health profile. Carriers have a better survival than non-carriers, as well as lower serum CRP levels. The 22-Glu-Lys-23 polymorphism is associated with a sex-specific, beneficial body composition at young-adult age, as well as greater muscle strength in males
Evidence & references
No separate evidence record is supplied for this statement.
Complete source annotation
{
"texts": [
{
"value": "Carriers of the 22-Glu-Lys-23 allele are relatively more resistant to the effects of GCs with respect to the sensitivity of the adrenal feedback mechanism than non-carriers, resulting in a better metabolic health profile. Carriers have a better survival than non-carriers, as well as lower serum CRP levels. The 22-Glu-Lys-23 polymorphism is associated with a sex-specific, beneficial body composition at young-adult age, as well as greater muscle strength in males"
}
],
"commentType": "POLYMORPHISM"
}Natural variants 28
Scroll across the table for evidence and actions.
28 recorded rows
| Feature | Position | Description | Evidence | Inspect |
|---|---|---|---|---|
| R23KVAR_014140 | 23 | reduces transactivation activity; does not affect transrepression activity; dbSNP:rs6190 R → K | Experimental evidence 7 publications Evidence & references
| No verified residues in this structure |
| F29LVAR_015628 | 29 | in dbSNP:rs148102613 F → L | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| F65VVAR_014622 | 65 | in dbSNP:rs6192 F → V | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| N72DVAR_075797 | 72 | associated in cis with A-321 and S-766 in one individual; doubles transactivation potential N → D | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| L112FVAR_015629 | 112 | in dbSNP:rs542110718 L → F | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| D233NVAR_015630 | 233 | in dbSNP:rs1241576112 D → N | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| V321AVAR_075798 | 321 | associated in cis with D-72 and S-766 in one individual; doubles transactivation potential V → A | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| N363SVAR_004675 | 363 | enhances transactivation activity; does not affect transrepression activity; may increase sensitivity to exogenously administered glucocorticoids; may contribute to central obesity in men and show lack of association with other risk factors for coronary heart disease and diabetes mellitus; dbSNP:rs56149945 N → S | Experimental evidence 6 publications Evidence & references
| No verified residues in this structure |
| C421YVAR_015631 | 421 | Natural variant C → Y | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| V423AVAR_075799 | 423 | in GCCR; uncertain significance; reduces transactivation activity; delays nuclear translocation; does not exert a dominant negative effect; impairs DNA binding V → A | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| R477HVAR_013472 | 477 | in GCCR; dbSNP:rs104893913 R → H | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| R477SVAR_077143 | 477 | in GCCR; loss of DNA-binding and of transactivation activity; incomplete dexamethasone-induced translocation to the nucleus; no effect on dexamethasone-binding affinity compared with wild-type R → S | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| Y478CVAR_077144 | 478 | in GCCR; decreased DNA-binding and transactivation activity; incomplete dexamethasone-induced translocation to the nucleus; no effect on dexamethasone-binding affinity compared with wild-type Y → C | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| T556IVAR_075800 | 556 | in GCCR; reduces transactivation activity; enhances transrepression activity; reduces affinity for ligand; delays nuclear translocation; does not exert a dominant negative effect; does not impair DNA binding T → I | Experimental evidence 2 publications Evidence & references
| No verified residues in this structure |
| I559NVAR_015632 | 559 | in GCCR; interferes with translocation to the nucleus and thereby strongly reduces transcription activation; is equally impaired in nuclear export; acts as dominant negative mutant; dbSNP:rs104893909 I → N | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| V571AVAR_025014 | 571 | in pseudohermaphroditism; female with hypokalemia due to glucocorticoid resistance; 6-fold reduction in binding affinity compared with the wild-type receptor; dbSNP:rs104893911 V → A | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| V575GVAR_075801 | 575 | in GCCR; uncertain significance; reduces transactivation activity; enhances transrepression activity; reduces affinity for ligand; delays nuclear translocation; does not exert a dominant negative effect; does not impair DNA binding V → G | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| D641VVAR_004676 | 641 | in GCCR; dbSNP:rs104893908 D → V | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| L672PVAR_077145 | 672 | in GCCR; loss of dexamethasone-binding, dexamethasone-induced translocation to the nucleus and of transactivation activity L → P | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| G679SVAR_013473 | 679 | in GCCR; has 50% binding affinity; dbSNP:rs104893914 G → S | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| R714QVAR_075802 | 714 | in GCCR; uncertain significance; reduces transactivation; reduces affinity for ligand; exerts a dominant negative effect; does not impair DNA binding R → Q | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| H726RVAR_075803 | 726 | in GCCR; uncertain significance; reduces transactivation and transrepression activity; reduces affinity for ligand; delays nuclear translocation; does not impair DNA binding H → R | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| V729IVAR_004677 | 729 | in GCCR; dbSNP:rs1027058734 V → I | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| F737LVAR_071935 | 737 | in GCCR; reduces transactivation of the glucocorticoid-inducible tumor virus promoter; reduces affinity for ligand; delays its nuclear translocation; acts as dominant negative mutant; dbSNP:rs121909727 F → L | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| I747MVAR_015633 | 747 | in GCCR; alters interaction with NCOA2 and strongly reduces transcription activation; acts as a dominant negative mutant; dbSNP:rs104893910 I → M | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| L753FVAR_004678 | 753 | in dbSNP:rs121909726 L → F | Experimental evidence 2 publications Evidence & references
| No verified residues in this structure |
| N766SVAR_075804 | 766 | associated in cis with D-72 and A-321 in one individual; doubles transactivation potential N → S | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| L773PVAR_071936 | 773 | in GCCR; reduces transactivation of the glucocorticoid-inducible tumor virus promoter; reduces affinity for ligand; delays its nuclear translocation; acts as dominant negative mutant; dbSNP:rs104893912 L → P | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
Laboratory mutagenesis 37
Scroll across the table for evidence and actions.
37 recorded rows
| Feature | Position | Description | Evidence | Inspect |
|---|---|---|---|---|
| M1T | 1 | Abolishes expression of A-type isoforms. M → T | Experimental evidence 2 publications Evidence & references
| No verified residues in this structure |
| M27T | 27 | Abolishes expression of B-type isoforms. M → T | Experimental evidence 2 publications Evidence & references
| No verified residues in this structure |
| M86I | 86 | Abolishes expression of C-type isoforms; when associated with I-90 and I-98. M → I | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| M90I | 90 | Abolishes expression of C-type isoforms; when associated with I-86 and I-98. M → I | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| M98I | 98 | Abolishes expression of C-type isoforms; when associated with I-86 and I-90. M → I | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| D101A | 101 | Reduces transcription activation activity of isoform Alpha-C3 by half. D → A | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| D101K | 101 | Reduces transcription activation activity of isoform Alpha-C3 by half. Suppresses apoptosis-inducing activity of isoform Alpha-C3. Impairs recruitment of selected coregulators onto DNA binding sites. D → K | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| QQ106LL | 106–107 | Reduces activity of isoform Alpha-C3 by half. QQ → LL | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| SS113AA | 113–114 | Does not affect the activity of isoform Alpha-C3. SS → AA | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| F191D | 191 | Reduces transactivation by the ADA complex. F → D | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| I193D | 193 | Reduces transactivation by the ADA complex. I → D | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| L194A | 194 | Strongly reduces transactivation by the ADA complex; when associated with V-224 and F-225. L → A | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| L197E | 197 | Reduces transactivation by the ADA complex. L → E | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| S211A | 211 | Reduces expression of target genes IGFBP1 and IRF8. S → A | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| W213A | 213 | Strongly reduces transactivation by the ADA complex. W → A | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| L224V | 224 | Strongly reduces transactivation by the ADA complex; when associated with A-194 and F-225. L → V | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| L225F | 225 | Strongly reduces transactivation by the ADA complex; when associated with A-194 and V-224. L → F | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| S226A | 226 | Abolishes phosphorylation and enhances transcriptional activation. S → A | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| F235L | 235 | Strongly reduces transactivation by the ADA complex; when associated with V-236. F → L | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| L236V | 236 | Strongly reduces transactivation by the ADA complex; when associated with L-235. L → V | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| K277R | 277 | Strongly reduces sumoylation. Almost complete loss of sumoylation; when associated with R-293. K → R | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| K293R | 293 | Strongly reduces sumoylation. Almost complete loss of sumoylation; when associated with R-277. K → R | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| M316I | 316 | Abolishes expression of D-type isoforms; when associated with I-331 and I-336. M → I | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| M331I | 331 | Abolishes expression of D-type isoforms; when associated with I-316 and I-336. M → I | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| M336I | 336 | Abolishes expression of D-type isoforms; when associated with I-316 and I-331. M → I | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| S404A | 404 | Abolishes phosphorylation. Does not affect translocation to the nucleus following ligand stimulation. Increases protein half-life and transcriptional repressor activity. Alters repertoire of regulated genes. Increases cell death. S → A | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| S404D | 404 | Does not affect translocation to the nucleus following ligand stimulation. S → D | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| K480A | 480 | Decrease in acetylation and in repression of its transcriptional activity by CLOCK-BMAL1 heterodimer. Complete loss in acetylation and in repression of its transcriptional activity by CLOCK-BMAL1 heterodimer; when associated with A-492; A-494 and A-495. K → A | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| K492A | 492 | Decrease in acetylation and in repression of its transcriptional activity by CLOCK-BMAL1 heterodimer. Complete loss in acetylation and in repression of its transcriptional activity by CLOCK-BMAL1 heterodimer; when associated with A-480; A-494 and A-495. K → A | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| K494A | 494 | Decrease in acetylation and in repression of its transcriptional activity by CLOCK-BMAL1 heterodimer; when associated with A-495. Complete loss in acetylation and in repression of its transcriptional activity by CLOCK-BMAL1 heterodimer; when associated with A-480; A-492 and A-495. K → A | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| K495A | 495 | Decrease in acetylation and in repression of its transcriptional activity by CLOCK-BMAL1 heterodimer; when associated with A-494. Complete loss in acetylation and in repression of its transcriptional activity by CLOCK-BMAL1 heterodimer; when associated with A-480; A-492 and A-494. K → A | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| R585A | 585 | Reduces activation mediated by ligand binding domain; when associated with A-590. R → A | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| D590A | 590 | Reduces activation mediated by ligand binding domain; when associated with A-585. D → A | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| F602S | 602 | Increases solubility. No effect on transactivation by dexamethasone. F → S | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| P625A | 625 | Decreases transactivation by dexamethasone by 95%. P → A | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| I628A | 628 | Decreases dimerization and transactivation by dexamethasone; when associated with S-602. I → A | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| K703R | 703 | Slightly reduces sumoylation. Inhibits the stimulatory effect of RWDD3 on its transcriptional activity. K → R | Experimental evidence 2 publications Evidence & references
| No verified residues in this structure |
PTM/Processing
Acetylation by CLOCK reduces its binding to glucocorticoid response elements and its transcriptional activity
Evidence & references
- ECO:0000269 PubMed:19141540 ↗
- ECO:0000269 PubMed:21980503 ↗
Complete source annotation
{
"texts": [
{
"evidences": [
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "19141540"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "21980503"
}
],
"value": "Acetylation by CLOCK reduces its binding to glucocorticoid response elements and its transcriptional activity"
}
],
"commentType": "PTM"
}Increased proteasome-mediated degradation in response to glucocorticoids [29]. Isoform Alpha-B appears to be more susceptible to proteolytic degradation than isoform Alpha [31]
Evidence & references
- ECO:0000269 PubMed:11435610 ↗
- ECO:0000269 PubMed:11555652 ↗
Complete source annotation
{
"texts": [
{
"evidences": [
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "11435610"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "11555652"
}
],
"value": "Increased proteasome-mediated degradation in response to glucocorticoids (PubMed:11555652). Isoform Alpha-B appears to be more susceptible to proteolytic degradation than isoform Alpha (PubMed:11435610)"
}
],
"commentType": "PTM"
}Phosphorylated in the absence of hormone; becomes hyperphosphorylated in the presence of glucocorticoid. The Ser-203, Ser-226 and Ser-404-phosphorylated forms are mainly cytoplasmic, and the Ser-211-phosphorylated form is nuclear [34, 46]. Phosphorylation at Ser-211 increases transcriptional activity [34, 47].
Phosphorylation at Ser-203, Ser-226 and Ser-404 decreases signaling capacity [34, 47, 46]. Phosphorylation at Ser-404 may protect from glucocorticoid-induced apoptosis [46]. Phosphorylation at Ser-203 and Ser-211 is not required in regulation of chromosome segregation [69].
May be dephosphorylated by PPP5C, attenuates NR3C1 action (By similarity)
Evidence & references
- ECO:0000250 UniProtKB:P06537
- ECO:0000269 PubMed:12000743 ↗
- ECO:0000269 PubMed:18483179 ↗
- ECO:0000269 PubMed:18838540 ↗
- ECO:0000269 PubMed:25847991 ↗
Complete source annotation
{
"texts": [
{
"evidences": [
{
"evidenceCode": "ECO:0000250",
"source": "UniProtKB",
"id": "P06537"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "12000743"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "18483179"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "18838540"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "25847991"
}
],
"value": "Phosphorylated in the absence of hormone; becomes hyperphosphorylated in the presence of glucocorticoid. The Ser-203, Ser-226 and Ser-404-phosphorylated forms are mainly cytoplasmic, and the Ser-211-phosphorylated form is nuclear (PubMed:12000743, PubMed:18838540). Phosphorylation at Ser-211 increases transcriptional activity (PubMed:12000743, PubMed:18483179). Phosphorylation at Ser-203, Ser-226 and Ser-404 decreases signaling capacity (PubMed:12000743, PubMed:18483179, PubMed:18838540). Phosphorylation at Ser-404 may protect from glucocorticoid-induced apoptosis (PubMed:18838540). Phosphorylation at Ser-203 and Ser-211 is not required in regulation of chromosome segregation (PubMed:25847991). May be dephosphorylated by PPP5C, attenuates NR3C1 action (By similarity)"
}
],
"commentType": "PTM"
}Ubiquitinated by UBR5, leading to its degradation: UBR5 specifically recognizes and binds ligand-bound NR3C1 when it is not associated with coactivators (NCOAs) [74]. In presence of NCOAs, the UBR5-degron is not accessible, preventing its ubiquitination and degradation [74]
Evidence & references
- ECO:0000269 PubMed:37478846 ↗
Complete source annotation
{
"texts": [
{
"evidences": [
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "37478846"
}
],
"value": "Ubiquitinated by UBR5, leading to its degradation: UBR5 specifically recognizes and binds ligand-bound NR3C1 when it is not associated with coactivators (NCOAs) (PubMed:37478846). In presence of NCOAs, the UBR5-degron is not accessible, preventing its ubiquitination and degradation (PubMed:37478846)"
}
],
"commentType": "PTM"
}Sumoylation at Lys-277 and Lys-293 negatively regulates its transcriptional activity [33]. Sumoylation at Lys-703 positively regulates its transcriptional activity in the presence of RWDD3 (By similarity). Sumoylation at Lys-277 and Lys-293 is dispensable whereas sumoylation at Lys-703 is critical for the stimulatory effect of RWDD3 on its transcriptional activity (By similarity).
Heat shock increases sumoylation in a RWDD3-dependent manner (By similarity)
Evidence & references
- ECO:0000250 UniProtKB:P06536
- ECO:0000269 PubMed:12144530 ↗
Complete source annotation
{
"texts": [
{
"evidences": [
{
"evidenceCode": "ECO:0000250",
"source": "UniProtKB",
"id": "P06536"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "12144530"
}
],
"value": "Sumoylation at Lys-277 and Lys-293 negatively regulates its transcriptional activity (PubMed:12144530). Sumoylation at Lys-703 positively regulates its transcriptional activity in the presence of RWDD3 (By similarity). Sumoylation at Lys-277 and Lys-293 is dispensable whereas sumoylation at Lys-703 is critical for the stimulatory effect of RWDD3 on its transcriptional activity (By similarity). Heat shock increases sumoylation in a RWDD3-dependent manner (By similarity)"
}
],
"commentType": "PTM"
}Processed chains & precursor regions 1
Scroll across the table for evidence and actions.
1 recorded rows
| Feature | Position | Description | Evidence | Inspect |
|---|---|---|---|---|
| ChainPRO_0000019937 | 1–777 | Glucocorticoid receptor | Evidence & referencesNo separate evidence record is supplied for this statement. | No verified residues in this structure |
Modifications 24
Scroll across the table for evidence and actions.
24 recorded rows
| Feature | Position | Description | Evidence | Inspect |
|---|---|---|---|---|
| Modified residue | 8 | Phosphothreonine | 1 publication Evidence & references
| No verified residues in this structure |
| Modified residue | 23 | Omega-N-methylarginine | By similarity Evidence & references
| No verified residues in this structure |
| Modified residue | 45 | Phosphoserine | 1 publication Evidence & references
| No verified residues in this structure |
| Modified residue | 113 | Phosphoserine | By similarity Evidence & references
| No verified residues in this structure |
| Modified residue | 134 | Phosphoserine | 1 publication Evidence & references
| No verified residues in this structure |
| Modified residue | 141 | Phosphoserine | By similarity Evidence & references
| No verified residues in this structure |
| Modified residue | 203 | Phosphoserine | Experimental evidence 4 publications Evidence & references
| No verified residues in this structure |
| Modified residue | 211 | Phosphoserine | Experimental evidence 3 publications Evidence & references
| No verified residues in this structure |
| Modified residue | 226 | Phosphoserine | Experimental evidence 2 publications Evidence & references
| No verified residues in this structure |
| Modified residue | 267 | Phosphoserine | 2 publications Evidence & references
| No verified residues in this structure |
| Modified residue | 404 | Phosphoserine; by GSK3-beta | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| Modified residue | 480 | N6-acetyllysine | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| Modified residue | 492 | N6-acetyllysine | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| Modified residue | 494 | N6-acetyllysine | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| Modified residue | 495 | N6-acetyllysine | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| Cross-link | 258 | Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2) | 1 publication Evidence & references
| No verified residues in this structure |
| Cross-link | 277 | Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO); alternate | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| Cross-link | 277 | Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate | 1 publication Evidence & references
| No verified residues in this structure |
| Cross-link | 293 | Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO); alternate | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| Cross-link | 293 | Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate | 1 publication Evidence & references
| No verified residues in this structure |
| Cross-link | 419 | Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin) | By similarity Evidence & references
| No verified residues in this structure |
| Cross-link | 703 | Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO) | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| Modified residue | 1 | N-acetylmethionineP04150-8 | 1 publication Evidence & references
| No verified residues in this structure · isoform-specific coordinates |
| Modified residue | 1 | N-acetylmethionineP04150-9 | 1 publication Evidence & references
| No verified residues in this structure · isoform-specific coordinates |
Expression
Widely expressed including bone, stomach, lung, liver, colon, breast, ovary, pancreas and kidney [69]. In the heart, detected in left and right atria, left and right ventricles, aorta, apex, intraventricular septum, and atrioventricular node as well as whole adult and fetal heart [25]
Evidence & references
- ECO:0000269 PubMed:10902803 ↗
- ECO:0000269 PubMed:25847991 ↗
Complete source annotation
{
"texts": [
{
"evidences": [
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "10902803"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "25847991"
}
],
"value": "Widely expressed including bone, stomach, lung, liver, colon, breast, ovary, pancreas and kidney (PubMed:25847991). In the heart, detected in left and right atria, left and right ventricles, aorta, apex, intraventricular septum, and atrioventricular node as well as whole adult and fetal heart (PubMed:10902803)"
}
],
"commentType": "TISSUE SPECIFICITY"
}Widely expressed including brain, bone marrow, thymus, spleen, liver, kidney, pancreas, lung, fat, skeletal muscle, heart, placenta and blood leukocytes
Evidence & references
- ECO:0000269 PubMed:7769088 ↗
- ECO:0000269 PubMed:8621628 ↗
Complete source annotation
{
"texts": [
{
"evidences": [
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "7769088"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "8621628"
}
],
"value": "Widely expressed including brain, bone marrow, thymus, spleen, liver, kidney, pancreas, lung, fat, skeletal muscle, heart, placenta and blood leukocytes"
}
],
"commentType": "TISSUE SPECIFICITY",
"molecule": "Isoform Beta"
}Widely expressed
Evidence & references
- ECO:0000269 PubMed:10566686 ↗
Complete source annotation
{
"texts": [
{
"evidences": [
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "10566686"
}
],
"value": "Widely expressed"
}
],
"commentType": "TISSUE SPECIFICITY",
"molecule": "Isoform Alpha-2"
}Induction
Isoform AlphaInduced by TNF (at protein level)
Evidence & references
- ECO:0000269 PubMed:11381138 ↗
Complete source annotation
{
"texts": [
{
"evidences": [
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "11381138"
}
],
"value": "Induced by TNF (at protein level)"
}
],
"commentType": "INDUCTION",
"molecule": "Isoform Alpha"
}Induced by TNF and becomes the predominant isoform which may lead to glucocorticoid resistance (at protein level)
Evidence & references
- ECO:0000269 PubMed:11381138 ↗
Complete source annotation
{
"texts": [
{
"evidences": [
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "11381138"
}
],
"value": "Induced by TNF and becomes the predominant isoform which may lead to glucocorticoid resistance (at protein level)"
}
],
"commentType": "INDUCTION",
"molecule": "Isoform Beta"
}Interaction
Documented interaction partners
UniProt’s filtered IntAct records. Experiment counts describe reported experiments, not binding strength or independent publications. Separate products remain separate rows.
| Partner / product | Species | Experiments | Evidence & actions |
|---|---|---|---|
| AKT1P31749With P04150 | Homo sapiens | 5 | IntAct evidenceSource product: P04150. Partner: P31749. Reported experiment count: 5. |
| CD4P01730With P04150 | Homo sapiens | 2 | IntAct evidenceSource product: P04150. Partner: P01730. Reported experiment count: 2. |
| EGFRP00533With P04150 | Homo sapiens | 3 | IntAct evidenceSource product: P04150. Partner: P00533. Reported experiment count: 3. |
| HNF4AP41235With P04150 | Homo sapiens | 2 | IntAct evidenceSource product: P04150. Partner: P41235. Reported experiment count: 2. |
| HSP90AA1P07900With P04150 | Homo sapiens | 8 | IntAct evidenceSource product: P04150. Partner: P07900. Reported experiment count: 8. |
| KIAA0408Q6ZU52With P04150 | Homo sapiens | 2 | IntAct evidenceSource product: P04150. Partner: Q6ZU52. Reported experiment count: 2. |
| LCKP06239With P04150 | Homo sapiens | 3 | IntAct evidenceSource product: P04150. Partner: P06239. Reported experiment count: 3. |
| RXRBP28702With P04150 | Homo sapiens | 4 | IntAct evidenceSource product: P04150. Partner: P28702. Reported experiment count: 4. |
| SEPTIN6Q14141With P04150 | Homo sapiens | 3 | IntAct evidenceSource product: P04150. Partner: Q14141. Reported experiment count: 3. |
| SOX14O95416With P04150 | Homo sapiens | 3 | IntAct evidenceSource product: P04150. Partner: O95416. Reported experiment count: 3. |
| TMF1P82094With P04150 | Homo sapiens | 3 | IntAct evidenceSource product: P04150. Partner: P82094. Reported experiment count: 3. |
| Asxl1P59598With P04150 | Mus musculusCross-species | 2 | IntAct evidenceSource product: P04150. Partner: P59598. Reported experiment count: 2. |
| MvpQ62667With P04150 | Rattus norvegicusCross-species | 2 | IntAct evidenceSource product: P04150. Partner: Q62667. Reported experiment count: 2. |
| Ncoa2Q61026With P04150-1 | Mus musculusCross-species | 3 | IntAct evidenceSource product: P04150-1. Partner: Q61026. Reported experiment count: 3. |
No partners match this filter.
Complex membership & assembly descriptions
Co-membership does not by itself prove direct binding between every pair.
No Complex Portal cross-reference was recorded for this entry.
UniProt subunit description
Heteromultimeric cytoplasmic complex with HSP90AA1, HSPA1A/HSPA1B, and FKBP5 or another immunophilin such as PPID, STIP1, or the immunophilin homolog PPP5C [57]. Upon ligand binding FKBP5 dissociates from the complex and FKBP4 takes its place, thereby linking the complex to dynein and mediating transport to the nucleus, where the complex dissociates (By similarity). Probably forms a complex composed of chaperones HSP90 and HSP70, co-chaperones CDC37, PPP5C, TSC1 and client protein TSC2, CDK4, AKT, RAF1 and NR3C1; this complex does not contain co-chaperones STIP1/HOP and PTGES3/p23 [71].
Directly interacts with UNC45A [43]. Binds to DNA as a homodimer, and as heterodimer with NR3C2 or the retinoid X receptor. Binds STAT5A and STAT5B homodimers and heterodimers (By similarity).
Interacts with NRIP1, POU2F1, POU2F2 and TRIM28 (By similarity). Interacts with several coactivator complexes, including the SMARCA4 complex, CREBBP/EP300, TADA2L (Ada complex) and p160 coactivators such as NCOA2 and NCOA6 [26, 75, 76, 21, 22]. Interaction with BAG1 inhibits transactivation [23].
Interacts with HEXIM1 and TGFB1I1 [35, 38, 41]. Interacts with NCOA1 [22]. Interacts with NCOA3, SMARCA4, SMARCC1, SMARCD1, and SMARCE1 (By similarity).
Interacts with CLOCK, CRY1 and CRY2 in a ligand-dependent fashion [50, 59, 58]. Interacts with CIART (By similarity). Interacts with RWDD3 (By similarity).
Interacts with UBE2I/UBC9 and this interaction is enhanced in the presence of RWDD3 (By similarity). Interacts with GRIP1 [94, 96]. Interacts with NR4A3 (via nuclear receptor DNA-binding domain), represses transcription activity of NR4A3 on the POMC promoter Nur response element (NurRE) [40].
Directly interacts with PNRC2 to attract and form a complex with UPF1 and DCP1A; the interaction leads to rapid mRNA degradation [68]. Interacts with GSK3B [46]. Interacts with FNIP1 and FNIP2 [70].
Interacts (via C-terminus) with HNRNPU (via C-terminus) [20]. Interacts with MCM3AP [42]. Interacts (via domain NR LBD) with HSP90AA1 and HSP90AB1 (By similarity).
In the absence of hormonal ligand, interacts with TACC1 [52]. Interacts (via NR LBD domain) with ZNF764 (via KRAB domain); the interaction regulates transcription factor activity of NR3C1 by directing its actions toward certain biologic pathways [73]
Evidence & references
- ECO:0000250 UniProtKB:P06536
- ECO:0000250 UniProtKB:P06537
- ECO:0000269 PubMed:10477749 ↗
- ECO:0000269 PubMed:10866662 ↗
- ECO:0000269 PubMed:12151000 ↗
- ECO:0000269 PubMed:12686538 ↗
- ECO:0000269 PubMed:15211577 ↗
- ECO:0000269 PubMed:15591535 ↗
- ECO:0000269 PubMed:15769988 ↗
- ECO:0000269 PubMed:15941832 ↗
- ECO:0000269 PubMed:16478993 ↗
- ECO:0000269 PubMed:16914116 ↗
- ECO:0000269 PubMed:17635946 ↗
- ECO:0000269 PubMed:18838540 ↗
- ECO:0000269 PubMed:19141540 ↗
- ECO:0000269 PubMed:20078863 ↗
- ECO:0000269 PubMed:21730050 ↗
- ECO:0000269 PubMed:21980503 ↗
- ECO:0000269 PubMed:22170608 ↗
- ECO:0000269 PubMed:25775514 ↗
- ECO:0000269 PubMed:27353360 ↗
- ECO:0000269 PubMed:28139699 ↗
- ECO:0000269 PubMed:29127155 ↗
- ECO:0000269 PubMed:9154805 ↗
- ECO:0000269 PubMed:9353307 ↗
- ECO:0000269 PubMed:9590696 ↗
Complete source annotation
{
"texts": [
{
"evidences": [
{
"evidenceCode": "ECO:0000250",
"source": "UniProtKB",
"id": "P06536"
},
{
"evidenceCode": "ECO:0000250",
"source": "UniProtKB",
"id": "P06537"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "10477749"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "10866662"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "12151000"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "12686538"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "15211577"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "15591535"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "15769988"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "15941832"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "16478993"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "16914116"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "17635946"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "18838540"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "19141540"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "20078863"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "21730050"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "21980503"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "22170608"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "25775514"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "27353360"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "28139699"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "29127155"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "9154805"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "9353307"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "9590696"
}
],
"value": "Heteromultimeric cytoplasmic complex with HSP90AA1, HSPA1A/HSPA1B, and FKBP5 or another immunophilin such as PPID, STIP1, or the immunophilin homolog PPP5C (PubMed:21730050). Upon ligand binding FKBP5 dissociates from the complex and FKBP4 takes its place, thereby linking the complex to dynein and mediating transport to the nucleus, where the complex dissociates (By similarity). Probably forms a complex composed of chaperones HSP90 and HSP70, co-chaperones CDC37, PPP5C, TSC1 and client protein TSC2, CDK4, AKT, RAF1 and NR3C1; this complex does not contain co-chaperones STIP1/HOP and PTGES3/p23 (PubMed:29127155). Directly interacts with UNC45A (PubMed:16478993). Binds to DNA as a homodimer, and as heterodimer with NR3C2 or the retinoid X receptor. Binds STAT5A and STAT5B homodimers and heterodimers (By similarity). Interacts with NRIP1, POU2F1, POU2F2 and TRIM28 (By similarity). Interacts with several coactivator complexes, including the SMARCA4 complex, CREBBP/EP300, TADA2L (Ada complex) and p160 coactivators such as NCOA2 and NCOA6 (PubMed:10866662, PubMed:12151000, PubMed:12686538, PubMed:9154805, PubMed:9590696). Interaction with BAG1 inhibits transactivation (PubMed:10477749). Interacts with HEXIM1 and TGFB1I1 (PubMed:12415108, PubMed:15211577, PubMed:15941832). Interacts with NCOA1 (PubMed:9590696). Interacts with NCOA3, SMARCA4, SMARCC1, SMARCD1, and SMARCE1 (By similarity). Interacts with CLOCK, CRY1 and CRY2 in a ligand-dependent fashion (PubMed:19141540, PubMed:21980503, PubMed:22170608). Interacts with CIART (By similarity). Interacts with RWDD3 (By similarity). Interacts with UBE2I/UBC9 and this interaction is enhanced in the presence of RWDD3 (By similarity). Interacts with GRIP1 (PubMed:15769988, PubMed:17635946). Interacts with NR4A3 (via nuclear receptor DNA-binding domain), represses transcription activity of NR4A3 on the POMC promoter Nur response element (NurRE) (PubMed:15591535). Directly interacts with PNRC2 to attract and form a complex with UPF1 and DCP1A; the interaction leads to rapid mRNA degradation (PubMed:25775514). Interacts with GSK3B (PubMed:18838540). Interacts with FNIP1 and FNIP2 (PubMed:27353360). Interacts (via C-terminus) with HNRNPU (via C-terminus) (PubMed:9353307). Interacts with MCM3AP (PubMed:16914116). Interacts (via domain NR LBD) with HSP90AA1 and HSP90AB1 (By similarity). In the absence of hormonal ligand, interacts with TACC1 (PubMed:20078863). Interacts (via NR LBD domain) with ZNF764 (via KRAB domain); the interaction regulates transcription factor activity of NR3C1 by directing its actions toward certain biologic pathways (PubMed:28139699)"
}
],
"commentType": "SUBUNIT"
}Other association resources
Resource links only; their association networks and counts are not added to the partner table.
Structure
7KW7 · Atomic cryoEM structure of Hsp90-Hsp70-Hop-GR
ELECTRON MICROSCOPY · 3.57 Å
Recorded components
| Component | Species | Chains | Protein identities |
|---|---|---|---|
| Heat shock protein HSP 90-alphaprotein · Entity 1 | Homo sapiens | A, B | P07900 |
| Heat shock 70 kDa protein 1Aprotein · Entity 2 | Homo sapiens | C, D | P0DMV8 |
| Stress-induced-phosphoprotein 1protein · Entity 3 | Homo sapiens | E | P31948 |
| Glucocorticoid receptorprotein · Entity 4 | Homo sapiens | F | P04150 |
| ADENOSINE-5'-DIPHOSPHATEligand · Entity 5 | G, J | No verified protein mapping | |
| MAGNESIUM IONligand · Entity 6 | H, K | No verified protein mapping | |
| POTASSIUM IONligand · Entity 7 | I, L | No verified protein mapping |
Biological assemblies
Assembly 1 · author_defined_assembly
Recorded chains: A, B, C, D, E, F, G, H, I, J, K, L
Assembly membership does not establish direct binding. Observed residue coverage is checked against the loaded coordinates; it is not inferred from construct metadata.
Publication
Structure of Hsp90-Hsp70-Hop-GR reveals the Hsp90 client-loading mechanism.
22/12/2021 · Read publication ↗
Detailed validation, construct lengths and deposition dates are not included in this published record. See the source record for those details.
PDB source record ↗Structure references are from the dated source record. Opening another structure follows your existing Atlas account permissions.
Available structures 59
Scroll across the table for evidence and actions.
59 recorded rows
| Record | Evidence type | Method | Resolution | Open |
|---|---|---|---|---|
| 7KW7 | experimental | EM | 3.57 A | Open in Atlas ↗ |
| 7PRW | experimental | X-ray | 2.50 A | Open in Atlas ↗ |
| 7PRV | experimental | X-ray | 2.70 A | Open in Atlas ↗ |
| 8FFV | experimental | EM | 3.01 A | Open in Atlas ↗ |
| 8FFW | experimental | EM | 3.23 A | Open in Atlas ↗ |
| 4UDD | experimental | X-ray | 1.80 A | Open in Atlas ↗ |
| 5NFP | experimental | X-ray | 2.10 A | Open in Atlas ↗ |
| 6EL7 | experimental | X-ray | 2.18 A | Open in Atlas ↗ |
| 6EL9 | experimental | X-ray | 2.19 A | Open in Atlas ↗ |
| 5G5W | experimental | X-ray | 2.20 A | Open in Atlas ↗ |
| 1NHZ | experimental | X-ray | 2.30 A | Open in Atlas ↗ |
| 4CSJ | experimental | X-ray | 2.30 A | Open in Atlas ↗ |
| 5NFT | experimental | X-ray | 2.30 A | Open in Atlas ↗ |
| 5G3J | experimental | X-ray | 2.40 A | Open in Atlas ↗ |
| 6EL6 | experimental | X-ray | 2.40 A | Open in Atlas ↗ |
| 5UC3 | experimental | X-ray | 2.01 A | Open in Atlas ↗ |
| 4P6W | experimental | X-ray | 1.95 A | Open in Atlas ↗ |
| 4UDC | experimental | X-ray | 2.50 A | Open in Atlas ↗ |
| 3K22 | experimental | X-ray | 2.10 A | Open in Atlas ↗ |
| 3E7C | experimental | X-ray | 2.15 A | Open in Atlas ↗ |
| 1P93 | experimental | X-ray | 2.70 A | Open in Atlas ↗ |
| 8VKZ | experimental | X-ray | 2.13 A | Open in Atlas ↗ |
| 7PRX | experimental | X-ray | 2.20 A | Open in Atlas ↗ |
| 4LSJ | experimental | X-ray | 2.35 A | Open in Atlas ↗ |
| 4MDD | experimental | X-ray | 2.40 A | Open in Atlas ↗ |
| 1M2Z | experimental | X-ray | 2.50 A | Open in Atlas ↗ |
| 7KRJ | experimental | EM | 2.56 A | Open in Atlas ↗ |
| 4P6X | experimental | X-ray | 2.50 A | Open in Atlas ↗ |
| 3BQD | experimental | X-ray | 2.50 A | Open in Atlas ↗ |
| 3CLD | experimental | X-ray | 2.84 A | Open in Atlas ↗ |
| 3H52 | experimental | X-ray | 2.80 A | Open in Atlas ↗ |
| 3K23 | experimental | X-ray | 3.00 A | Open in Atlas ↗ |
| 6DXK | experimental | X-ray | 3.05 A | Open in Atlas ↗ |
| 5E69 | experimental | X-ray | 1.85 A | Open in Atlas ↗ |
| 4HN5 | experimental | X-ray | 1.90 A | Open in Atlas ↗ |
| 5CBX | experimental | X-ray | 2.00 A | Open in Atlas ↗ |
| 5CBY | experimental | X-ray | 2.00 A | Open in Atlas ↗ |
| 5E6A | experimental | X-ray | 2.20 A | Open in Atlas ↗ |
| 5E6C | experimental | X-ray | 2.20 A | Open in Atlas ↗ |
| 5E6B | experimental | X-ray | 2.25 A | Open in Atlas ↗ |
| 5CC1 | experimental | X-ray | 2.30 A | Open in Atlas ↗ |
| 5EMC | experimental | X-ray | 2.30 A | Open in Atlas ↗ |
| 5EMP | experimental | X-ray | 2.30 A | Open in Atlas ↗ |
| 5EMQ | experimental | X-ray | 2.30 A | Open in Atlas ↗ |
| 6X6E | experimental | X-ray | 2.00 A | Open in Atlas ↗ |
| 5CBZ | experimental | X-ray | 2.20 A | Open in Atlas ↗ |
| 5E6D | experimental | X-ray | 2.40 A | Open in Atlas ↗ |
| 6CFN | experimental | X-ray | 2.50 A | Open in Atlas ↗ |
| 4HN6 | experimental | X-ray | 2.55 A | Open in Atlas ↗ |
| 5VA7 | experimental | X-ray | 2.15 A | Open in Atlas ↗ |
| 5VA0 | experimental | X-ray | 2.29 A | Open in Atlas ↗ |
| 6X6D | experimental | X-ray | 2.48 A | Open in Atlas ↗ |
| 6BQU | experimental | X-ray | 2.50 A | Open in Atlas ↗ |
| 8A9G | experimental | X-ray | 1.96 A | Open in Atlas ↗ |
| 6YMO | experimental | X-ray | 2.02 A | Open in Atlas ↗ |
| 5UC1 | experimental | X-ray | 2.35 A | Open in Atlas ↗ |
| 6YO8 | experimental | X-ray | 2.09 A | Open in Atlas ↗ |
| 6YOS | experimental | X-ray | 2.75 A | Open in Atlas ↗ |
| AF-P04150-F1 | predicted | AlphaFold | Not applicable | Open in Atlas ↗ |
Family & Domains
Composed of three domains: a modulating N-terminal domain, a DNA-binding domain and a C-terminal ligand-binding domain [16]. The ligand-binding domain is required for correct chromosome segregation during mitosis although ligand binding is not required [69]
Evidence & references
- ECO:0000269 PubMed:25847991 ↗
- ECO:0000269 PubMed:3841189 ↗
Complete source annotation
{
"texts": [
{
"evidences": [
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "25847991"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "3841189"
}
],
"value": "Composed of three domains: a modulating N-terminal domain, a DNA-binding domain and a C-terminal ligand-binding domain (PubMed:3841189). The ligand-binding domain is required for correct chromosome segregation during mitosis although ligand binding is not required (PubMed:25847991)"
}
],
"commentType": "DOMAIN"
}Belongs to the nuclear hormone receptor family. NR3 subfamily
Evidence & references
- ECO:0000305
Complete source annotation
{
"texts": [
{
"evidences": [
{
"evidenceCode": "ECO:0000305"
}
],
"value": "Belongs to the nuclear hormone receptor family. NR3 subfamily"
}
],
"commentType": "SIMILARITY"
}Domain architecture
Canonical coordinates. Overlapping marks share a lane; individual records and evidence are in the tables below. Gaps in coverage are not selectable in 3D. Use the track links and tables for keyboard inspection.
Atlas domains, motifs & repeats 2
Scroll across the table for evidence and actions.
2 recorded rows
| Annotation | Position | Source & interpretation | Inspect |
|---|---|---|---|
| Zinc finger, nuclear hormone receptor-typeIPR001628 | 418–493 | INTERPROdomain This entry represents the two C4-type zinc finger modules involved in DNA-binding. Steroid or nuclear hormone receptors constitute an important superfamily of transcription regulators that are involved in widely diverse physiological functions, including control of embryonic development, cell differentiation and homeostasis. Full source descriptionThis entry represents the two C4-type zinc finger modules involved in DNA-binding. Steroid or nuclear hormone receptors constitute an important superfamily of transcription regulators that are involved in widely diverse physiological functions, including control of embryonic development, cell differentiation and homeostasis. The receptors function as dimeric molecules in nuclei to regulate the transcription of target genes in a ligand-responsive manner. Nuclear hormone receptors consist of a highly conserved DNA-binding domain that recognises specific sequences, connected via a linker region to a C-terminal ligand-binding domain ([interpro:IPR000536]). In addition, certain nuclear hormone receptors have an N-terminal modulatory domain ([interpro:IPR001292]). The DNA-binding domain can elicit either an activating or repressing effect by binding to specific regions of the DNA known as hormone-response elements. These response elements position the receptors, and the complexes recruited by them, close to the genes of which transcription is affected. The DNA-binding domains of nuclear receptors consist of two zinc-nucleated modules and a C-terminal extension, where residues in the first zinc module determine the specificity of the DNA recognition and residues in the second zinc module are involved in dimerisation. The DNA-binding domain is furthermore involved in several other functions including nuclear localisation, and interaction with transcription factors and co-activators. Zinc finger (Znf) domains are relatively small protein motifs which contain multiple finger-like protrusions that make tandem contacts with their target molecule. Some of these domains bind zinc, but many do not; instead, they bind other metals, such as iron, or no metal at all. For example, some family members form salt bridges to stabilise the finger-like folds. They were first identified as a DNA-binding motif in transcription factor TFIIIA from Xenopus laevis (African clawed frog); however, they are now recognised to bind DNA, RNA, protein and/or lipid substrates. Their binding properties depend on the amino acid sequence of the finger domains and of the linker between fingers, as well as on the higher-order structures and the number of fingers. Znf domains are often found in clusters, where fingers can have different binding specificities. There are many superfamilies of Znf motifs, varying in both sequence and structure. They display considerable versatility in binding modes, even between members of the same class (e.g., some bind DNA, others protein), suggesting that Znf motifs are stable scaffolds that have evolved specialised functions. For example, Znf-containing proteins function in gene transcription, translation, mRNA trafficking, cytoskeleton organisation, epithelial development, cell adhesion, protein folding, chromatin remodelling and zinc sensing, to name but a few. Zinc-binding motifs are stable structures, and they rarely undergo conformational changes upon binding their target. | No verified residues in this structure |
| Nuclear hormone receptor, ligand-binding domainIPR000536 | 524–758 | INTERPROdomain Nuclear receptors (NRs), such as the receptors for steroids and thyroid hormones, retinoids and vitamin D3, are one of the most abundant classes of transcriptional regulators in animals (metazoans). They regulate diverse functions, such as homeostasis, reproduction, development and metabolism. Full source descriptionNuclear receptors (NRs), such as the receptors for steroids and thyroid hormones, retinoids and vitamin D3, are one of the most abundant classes of transcriptional regulators in animals (metazoans). They regulate diverse functions, such as homeostasis, reproduction, development and metabolism. The most prominent feature differentiating them from other transcription factors is their capacity to bind small hydrophobic molecules specifically. These ligands constitute regulatory signals, which modify the NR transcriptional activity through conformational changes. Prototypical NRs share a common structural organisation with a variable N-terminal domain that contains a constitutively active activation function (AF)-1, a conserved DNA- binding domain (DBD) consisting of two zinc fingers, a linker region, and a C-terminal ligand-binding domain (LBD), also called HOLI domain. The NR LBD plays a crucial role in ligand-mediated NR activity. In addition to its role is ligand recognition, the LBD also contains a ligand-dependent AF-2. Conformational changes in AF-2 induced by various ligands can modulate interactions with conserved motifs of coregulatory proteins. Specifically, the binding of ligands to the LBD determines the recruiting of transcriptional coregulators which triggers induction or repression of target genes. The coregulators include coactivators like the p160 factors also referred to as the steroid receptor coactivators (SRC) family, and corepressors such as SMART (silencing mediator for retinoid and thyroid hormone receptors) and N-CoR (nuclear corepressor). The overall structure of NR LBD is composed of about 11-13 α-helices that are arranged into a three-layer antiparallel α-helical sandwich with the three long helices (helices 3, 7, and 10) forming the two outer layers. The middle layer of helices (helices 4, 5, 8 and 9) is present only in the top half of the domain but is missing from the bottom half, thereby creating a cavity, so called ligand-binding pocket, for ligand binding in most receptors. The bound ligands stabilize the NR conformation through direct contacts with multiple structural elements including helices H3, H5, H6, H7, H10, and the loop proceeding the AF-2 helix. The C-terminal activation region also forms an α-helix (AF-2), which can adopt multiple conformation depending on the nature of the bound ligand. Helices 3,4 and 12 enclose a shallow hydrophobic groove which is the site for coregulator binding. Despite the conserved fold of NR LBDs, the ligand-binding pocket is the least conserved region among different NR LBDs. | No verified residues in this structure |
UniProt domains, repeats & motifs 1
Scroll across the table for evidence and actions.
1 recorded rows
| Feature | Position | Description | Evidence | Inspect |
|---|---|---|---|---|
| Domain | 524–758 | NR LBD | Sequence analysis Evidence & references
| No verified residues in this structure |
Functional sites 3
Scroll across the table for evidence and actions.
3 recorded rows
| Feature | Position | Description | Evidence | Inspect |
|---|---|---|---|---|
| DNA binding | 418–493 | Nuclear receptor | Sequence analysis Evidence & references
| No verified residues in this structure |
| Zinc finger | 421–441 | NR C4-type | Sequence analysis Evidence & references
| No verified residues in this structure |
| Zinc finger | 457–476 | NR C4-type | Sequence analysis Evidence & references
| No verified residues in this structure |
Sequence regions 14
Scroll across the table for evidence and actions.
14 recorded rows
| Feature | Position | Description | Evidence | Inspect |
|---|---|---|---|---|
| Region | 1–420 | Modulating | Evidence & referencesNo separate evidence record is supplied for this statement. | No verified residues in this structure |
| Region | 1–23 | Disordered | Evidence & references
| No verified residues in this structure |
| Region | 98–115 | Required for high transcriptional activity of isoform Alpha-C3 | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| Region | 130–183 | Disordered | Evidence & references
| No verified residues in this structure |
| Region | 394–415 | Disordered | Evidence & references
| No verified residues in this structure |
| Region | 485–777 | Interaction with CLOCK | Evidence & referencesNo separate evidence record is supplied for this statement. | No verified residues in this structure |
| Region | 487–523 | Hinge | Evidence & referencesNo separate evidence record is supplied for this statement. | No verified residues in this structure |
| Region | 532–697 | Interaction with CRY1 | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| Compositional bias | 1–14 | Basic and acidic residues | Evidence & references
| No verified residues in this structure |
| Compositional bias | 130–140 | Polar residues | Evidence & references
| No verified residues in this structure |
| Compositional bias | 141–150 | Low complexity | Evidence & references
| No verified residues in this structure |
| Compositional bias | 152–163 | Basic and acidic residues | Evidence & references
| No verified residues in this structure |
| Compositional bias | 164–174 | Polar residues | Evidence & references
| No verified residues in this structure |
| Compositional bias | 394–414 | Low complexity | Evidence & references
| No verified residues in this structure |
Sequence & Isoforms
Sequence & isoforms
UniProt’s canonical sequence is its selected representative. It is not necessarily the dominant isoform in every tissue.
The mass describes this unmodified source sequence, not every mature or modified product.
MDSKESLTPGREENPSSVLAQERGDVMDFYKTLRGGATVKVSASSPSLAVASQSDSKQRRLLVDFPKGSVSNAQQPDLSKAVSLSMGLYMGETETKVMGNDLGFPQQGQISLSSGETDLKLLEESIANLNRSTSVPENPKSSASTAVSAAPTEKEFPKTHSDVSSEQQHLKGQTGTNGGNVKLYTTDQSTFDILQDLEFSSGSPGKETNESPWRSDLLIDENCLLSPLAGEDDSFLLEGNSNEDCKPLILPDTKPKIKDNGDLVLSSPSNVTLPQVKTEKEDFIELCTPGVIKQEKLGTVYCQASFPGANIIGNKMSAISVHGVSTSGGQMYHYDMNTASLSQQQDQKPIFNVIPPIPVGSENWNRCQGSGDDNLTSLGTLNFPGRTVFSNGYSSPSMRPDVSSPPSSSSTATTGPPPKLCLVCSDEASGCHYGVLTCGSCKVFFKRAVEGQHNYLCAGRNDCIIDKIRRKNCPACRYRKCLQAGMNLEARKTKKKIKGIQQATTGVSQETSENPGNKTIVPATLPQLTPTLVSLLEVIEPEVLYAGYDSSVPDSTWRIMTTLNMLGGRQVIAAVKWAKAIPGFRNLHLDDQMTLLQYSWMFLMAFALGWRSYRQSSANLLCFAPDLIINEQRMTLPCMYDQCKHMLYVSSELHRLQVSYEEYLCMKTLLLLSSVPKDGLKSQELFDEIRMTYIKELGKAIVKREGNSSQNWQRFYQLTKLLDSMHEVVENLLNYCFQTFLDKTMSIEFPEMLAEIITNQIPKYSNGNIKKLLFHQKSource isoform notes & selection
Alternative splicing · Alternative initiation
Complete source annotation
{
"commentType": "ALTERNATIVE PRODUCTS",
"events": [
"Alternative splicing",
"Alternative initiation"
],
"isoforms": [
{
"name": {
"value": "Alpha"
},
"synonyms": [
{
"value": "Alpha-A"
},
{
"value": "GR-alphaA"
}
],
"isoformIds": [
"P04150-1"
],
"isoformSequenceStatus": "Displayed"
},
{
"name": {
"value": "Beta"
},
"synonyms": [
{
"value": "Beta-A"
}
],
"isoformIds": [
"P04150-2"
],
"sequenceIds": [
"VSP_003703"
],
"isoformSequenceStatus": "Described"
},
{
"name": {
"value": "Alpha-2"
},
"synonyms": [
{
"value": "Gamma"
}
],
"isoformIds": [
"P04150-3"
],
"sequenceIds": [
"VSP_007363"
],
"isoformSequenceStatus": "Described"
},
{
"name": {
"value": "Beta-2"
},
"isoformIds": [
"P04150-6"
],
"sequenceIds": [
"VSP_007363",
"VSP_003703"
],
"isoformSequenceStatus": "Described"
},
{
"name": {
"value": "GR-A alpha"
},
"isoformIds": [
"P04150-5"
],
"sequenceIds": [
"VSP_013340"
],
"isoformSequenceStatus": "Described"
},
{
"name": {
"value": "GR-A beta"
},
"isoformIds": [
"P04150-7"
],
"sequenceIds": [
"VSP_013340",
"VSP_003703"
],
"isoformSequenceStatus": "Described"
},
{
"name": {
"value": "GR-P"
},
"isoformIds": [
"P04150-4"
],
"isoformSequenceStatus": "Not described"
},
{
"name": {
"value": "Alpha-B"
},
"synonyms": [
{
"value": "GR-alphaB"
}
],
"isoformIds": [
"P04150-8"
],
"sequenceIds": [
"VSP_018773"
],
"isoformSequenceStatus": "Described"
},
{
"name": {
"value": "Beta-B"
},
"isoformIds": [
"P04150-9"
],
"sequenceIds": [
"VSP_018773",
"VSP_003703"
],
"isoformSequenceStatus": "Described"
},
{
"name": {
"value": "10"
},
"synonyms": [
{
"value": "hGRDelta313-338"
}
],
"isoformIds": [
"P04150-10"
],
"sequenceIds": [
"VSP_043908"
],
"isoformSequenceStatus": "Described"
},
{
"name": {
"value": "Alpha-C1"
},
"synonyms": [
{
"value": "GR-alphaC1"
}
],
"isoformIds": [
"P04150-11"
],
"sequenceIds": [
"VSP_058317"
],
"isoformSequenceStatus": "Described"
},
{
"name": {
"value": "Alpha-C2"
},
"synonyms": [
{
"value": "GR-alphaC2"
}
],
"isoformIds": [
"P04150-12"
],
"sequenceIds": [
"VSP_058316"
],
"isoformSequenceStatus": "Described"
},
{
"name": {
"value": "Alpha-C3"
},
"synonyms": [
{
"value": "GR-alphaC3"
}
],
"isoformIds": [
"P04150-13"
],
"sequenceIds": [
"VSP_058315"
],
"isoformSequenceStatus": "Described"
},
{
"name": {
"value": "Alpha-D1"
},
"synonyms": [
{
"value": "GR-alphaD1"
}
],
"isoformIds": [
"P04150-14"
],
"sequenceIds": [
"VSP_058314"
],
"isoformSequenceStatus": "Described"
},
{
"name": {
"value": "Alpha-D2"
},
"synonyms": [
{
"value": "GR-alphaD2"
}
],
"isoformIds": [
"P04150-15"
],
"sequenceIds": [
"VSP_058313"
],
"isoformSequenceStatus": "Described"
},
{
"name": {
"value": "Alpha-D3"
},
"synonyms": [
{
"value": "GR-alphaD3"
}
],
"isoformIds": [
"P04150-16"
],
"sequenceIds": [
"VSP_058312"
],
"isoformSequenceStatus": "Described"
}
]
}- P04150-1 · Alpha · Displayed · Alpha-A, GR-alphaA
Complete source annotation
{ "name": { "value": "Alpha" }, "synonyms": [ { "value": "Alpha-A" }, { "value": "GR-alphaA" } ], "isoformIds": [ "P04150-1" ], "isoformSequenceStatus": "Displayed" } - P04150-2 · Beta · Described · Beta-A · VSP_003703
Complete source annotation
{ "name": { "value": "Beta" }, "synonyms": [ { "value": "Beta-A" } ], "isoformIds": [ "P04150-2" ], "sequenceIds": [ "VSP_003703" ], "isoformSequenceStatus": "Described" } - P04150-3 · Alpha-2 · Described · Gamma · VSP_007363
Complete source annotation
{ "name": { "value": "Alpha-2" }, "synonyms": [ { "value": "Gamma" } ], "isoformIds": [ "P04150-3" ], "sequenceIds": [ "VSP_007363" ], "isoformSequenceStatus": "Described" } - P04150-6 · Beta-2 · Described · VSP_007363, VSP_003703
Complete source annotation
{ "name": { "value": "Beta-2" }, "isoformIds": [ "P04150-6" ], "sequenceIds": [ "VSP_007363", "VSP_003703" ], "isoformSequenceStatus": "Described" } - P04150-5 · GR-A alpha · Described · VSP_013340
Complete source annotation
{ "name": { "value": "GR-A alpha" }, "isoformIds": [ "P04150-5" ], "sequenceIds": [ "VSP_013340" ], "isoformSequenceStatus": "Described" } - P04150-7 · GR-A beta · Described · VSP_013340, VSP_003703
Complete source annotation
{ "name": { "value": "GR-A beta" }, "isoformIds": [ "P04150-7" ], "sequenceIds": [ "VSP_013340", "VSP_003703" ], "isoformSequenceStatus": "Described" } - P04150-4 · GR-P · Not described
Complete source annotation
{ "name": { "value": "GR-P" }, "isoformIds": [ "P04150-4" ], "isoformSequenceStatus": "Not described" } - P04150-8 · Alpha-B · Described · GR-alphaB · VSP_018773
Complete source annotation
{ "name": { "value": "Alpha-B" }, "synonyms": [ { "value": "GR-alphaB" } ], "isoformIds": [ "P04150-8" ], "sequenceIds": [ "VSP_018773" ], "isoformSequenceStatus": "Described" } - P04150-9 · Beta-B · Described · VSP_018773, VSP_003703
Complete source annotation
{ "name": { "value": "Beta-B" }, "isoformIds": [ "P04150-9" ], "sequenceIds": [ "VSP_018773", "VSP_003703" ], "isoformSequenceStatus": "Described" } - P04150-10 · 10 · Described · hGRDelta313-338 · VSP_043908
Complete source annotation
{ "name": { "value": "10" }, "synonyms": [ { "value": "hGRDelta313-338" } ], "isoformIds": [ "P04150-10" ], "sequenceIds": [ "VSP_043908" ], "isoformSequenceStatus": "Described" } - P04150-11 · Alpha-C1 · Described · GR-alphaC1 · VSP_058317
Complete source annotation
{ "name": { "value": "Alpha-C1" }, "synonyms": [ { "value": "GR-alphaC1" } ], "isoformIds": [ "P04150-11" ], "sequenceIds": [ "VSP_058317" ], "isoformSequenceStatus": "Described" } - P04150-12 · Alpha-C2 · Described · GR-alphaC2 · VSP_058316
Complete source annotation
{ "name": { "value": "Alpha-C2" }, "synonyms": [ { "value": "GR-alphaC2" } ], "isoformIds": [ "P04150-12" ], "sequenceIds": [ "VSP_058316" ], "isoformSequenceStatus": "Described" } - P04150-13 · Alpha-C3 · Described · GR-alphaC3 · VSP_058315
Complete source annotation
{ "name": { "value": "Alpha-C3" }, "synonyms": [ { "value": "GR-alphaC3" } ], "isoformIds": [ "P04150-13" ], "sequenceIds": [ "VSP_058315" ], "isoformSequenceStatus": "Described" } - P04150-14 · Alpha-D1 · Described · GR-alphaD1 · VSP_058314
Complete source annotation
{ "name": { "value": "Alpha-D1" }, "synonyms": [ { "value": "GR-alphaD1" } ], "isoformIds": [ "P04150-14" ], "sequenceIds": [ "VSP_058314" ], "isoformSequenceStatus": "Described" } - P04150-15 · Alpha-D2 · Described · GR-alphaD2 · VSP_058313
Complete source annotation
{ "name": { "value": "Alpha-D2" }, "synonyms": [ { "value": "GR-alphaD2" } ], "isoformIds": [ "P04150-15" ], "sequenceIds": [ "VSP_058313" ], "isoformSequenceStatus": "Described" } - P04150-16 · Alpha-D3 · Described · GR-alphaD3 · VSP_058312
Complete source annotation
{ "name": { "value": "Alpha-D3" }, "synonyms": [ { "value": "GR-alphaD3" } ], "isoformIds": [ "P04150-16" ], "sequenceIds": [ "VSP_058312" ], "isoformSequenceStatus": "Described" }
Isoform sequence differences 11
Scroll across the table for evidence and actions.
11 recorded rows
| Feature | Position | Description | Evidence | Inspect |
|---|---|---|---|---|
| Alternative sequenceVSP_058312 | 1–335 | in isoform Alpha-D3 | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| Alternative sequenceVSP_058313 | 1–330 | in isoform Alpha-D2 | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| Alternative sequenceVSP_058314 | 1–315 | in isoform Alpha-D1 | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| Alternative sequenceVSP_058315 | 1–97 | in isoform Alpha-C3 | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| Alternative sequenceVSP_058316 | 1–89 | in isoform Alpha-C2 | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| Alternative sequenceVSP_058317 | 1–85 | in isoform Alpha-C1 | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| Alternative sequenceVSP_018773 | 1–26 | in isoform Alpha-B and isoform Beta-B | Curator inference Evidence & references
| No verified residues in this structure |
| Alternative sequenceVSP_043908 | 313–338 | in isoform 10 | Published statement 1 publication Evidence & references
| No verified residues in this structure |
| Alternative sequenceVSP_007363 | 451 | in isoform Alpha-2 and isoform Beta-2 G → GR | Published statement Evidence & references
| No verified residues in this structure |
| Alternative sequenceVSP_013340 | 491–674 | in isoform GR-A alpha and isoform GR-A beta | Curator inference Evidence & references
| No verified residues in this structure |
| Alternative sequenceVSP_003703 | 728–777 | in isoform Beta, isoform Beta-B, isoform Beta-2 and isoform GR-A beta VVENLLNYCFQTFLDKTMSIEFPEMLAEIITNQIPKYSNGNIKKLLFHQK → NVMWLKPESTSHTLI | Published statement 1 publication Evidence & references
| No verified residues in this structure |
Sequence conflicts & cautions 2
Scroll across the table for evidence and actions.
2 recorded rows
| Feature | Position | Description | Evidence | Inspect |
|---|---|---|---|---|
| Sequence conflict | 399 | in Ref. 7; BAD97314 R → G | Curator inference Evidence & references
| No verified residues in this structure |
| Sequence conflict | 754 | in Ref. 7; BAD97314 A → T | Curator inference Evidence & references
| No verified residues in this structure |
Recorded secondary structure 31
Scroll across the table for evidence and actions.
31 recorded rows
| Feature | Position | Description | Evidence | Inspect |
|---|---|---|---|---|
| Helix | 416–419 | Helix | Evidence & references
| No verified residues in this structure |
| Turn | 422–424 | Turn | Evidence & references
| No verified residues in this structure |
| Beta strand | 430–432 | Beta strand | Evidence & references
| No verified residues in this structure |
| Beta strand | 435–437 | Beta strand | Evidence & references
| No verified residues in this structure |
| Helix | 439–450 | Helix | Evidence & references
| No verified residues in this structure |
| Beta strand | 458–461 | Beta strand | Evidence & references
| No verified residues in this structure |
| Turn | 467–472 | Turn | Evidence & references
| No verified residues in this structure |
| Helix | 474–484 | Helix | Evidence & references
| No verified residues in this structure |
| Helix | 488–497 | Helix | Evidence & references
| No verified residues in this structure |
| Helix | 520–523 | Helix | Evidence & references
| No verified residues in this structure |
| Beta strand | 527–529 | Beta strand | Evidence & references
| No verified residues in this structure |
| Helix | 532–538 | Helix | Evidence & references
| No verified residues in this structure |
| Helix | 540–545 | Helix | Evidence & references
| No verified residues in this structure |
| Beta strand | 550–552 | Beta strand | Evidence & references
| No verified residues in this structure |
| Helix | 556–579 | Helix | Evidence & references
| No verified residues in this structure |
| Helix | 584–586 | Helix | Evidence & references
| No verified residues in this structure |
| Helix | 589–615 | Helix | Evidence & references
| No verified residues in this structure |
| Beta strand | 617–619 | Beta strand | Evidence & references
| No verified residues in this structure |
| Beta strand | 621–624 | Beta strand | Evidence & references
| No verified residues in this structure |
| Beta strand | 627–629 | Beta strand | Evidence & references
| No verified residues in this structure |
| Helix | 631–634 | Helix | Evidence & references
| No verified residues in this structure |
| Helix | 639–655 | Helix | Evidence & references
| No verified residues in this structure |
| Helix | 660–671 | Helix | Evidence & references
| No verified residues in this structure |
| Beta strand | 673–675 | Beta strand | Evidence & references
| No verified residues in this structure |
| Helix | 683–702 | Helix | Evidence & references
| No verified residues in this structure |
| Beta strand | 704–706 | Beta strand | Evidence & references
| No verified residues in this structure |
| Helix | 708–741 | Helix | Evidence & references
| No verified residues in this structure |
| Helix | 743–745 | Helix | Evidence & references
| No verified residues in this structure |
| Helix | 751–765 | Helix | Evidence & references
| No verified residues in this structure |
| Helix | 766–768 | Helix | Evidence & references
| No verified residues in this structure |
| Beta strand | 769–771 | Beta strand | Evidence & references
| No verified residues in this structure |
Homologs
OMA orthologs
Evolutionary relationships assigned by OMA, kept separate from sequence clusters. “1:1” describes an orthology relationship, not percentage identity.
Recorded preview of up to 12 orthologs; not an exhaustive list. Entries without a verified UniProt mapping open their OMA record.
Sources & References
Scientific descriptions and evidence come from the named sources. Atlas assembles the presentation and verifies residue mappings; it does not independently curate these claims.
Source dates & provenance
- UniProt / The UniProt Consortium ↗ · 2026-11-09T11:39:40.193503+00:00
- InterPro / EMBL-EBI and the member sources identified in the annotations ↗ · 2026-11-09T11:39:40.086034+00:00
- AlphaFold DB / DeepMind Technologies Limited / EMBL-EBI ↗ · 2026-11-09T11:39:41.770639+00:00
- UniProt / The UniProt Consortium ↗ · 2026-11-09T11:39:40.193503+00:00
- InterPro / EMBL-EBI and the member sources identified in the annotations ↗ · 2026-11-09T11:39:40.086034+00:00
- AlphaFold DB / DeepMind Technologies Limited / EMBL-EBI ↗ · 2026-11-09T11:39:41.770639+00:00
- UniProt overview ↗ · 2026-11-10T20:42:44.745182+00:00
- www.ebi.ac.uk ↗ · 2026-11-10T21:11:27.591671+00:00
- rest.uniprot.org ↗ · 2026-11-10T21:11:27.600435+00:00
- www.ebi.ac.uk ↗ · 2026-11-10T21:11:27.633410+00:00
- omabrowser.org ↗ · 2026-11-10T21:11:27.677123+00:00
- omabrowser.org ↗ · 2026-11-10T21:11:27.723035+00:00
- rest.uniprot.org ↗ · 2026-11-10T21:11:28.223807+00:00
- rest.uniprot.org ↗ · 2026-11-10T21:11:28.251727+00:00
- rest.uniprot.org ↗ · 2026-11-10T21:11:29.177639+00:00
- rest.uniprot.org ↗ · 2026-11-10T21:11:29.219281+00:00
- rest.uniprot.org ↗ · 2026-11-10T21:11:30.259183+00:00
- rest.uniprot.org ↗ · 2026-11-10T21:11:30.449629+00:00
- rest.uniprot.org ↗ · 2026-11-10T21:11:31.195371+00:00
- rest.uniprot.org ↗ · 2026-11-10T21:11:31.368383+00:00
- rest.uniprot.org ↗ · 2026-11-10T21:11:32.251777+00:00
- rest.uniprot.org ↗ · 2026-11-10T21:11:32.267652+00:00
- rest.uniprot.org ↗ · 2026-11-10T21:11:33.286093+00:00
- rest.uniprot.org ↗ · 2026-11-10T21:11:33.289538+00:00
- rest.uniprot.org ↗ · 2026-11-10T21:11:34.162250+00:00
- rest.uniprot.org ↗ · 2026-11-10T21:11:35.329721+00:00
- rest.uniprot.org ↗ · 2026-11-10T21:11:36.391673+00:00
- rest.uniprot.org ↗ · 2026-11-10T21:11:37.226533+00:00
- rest.uniprot.org ↗ · 2026-11-10T21:11:37.257270+00:00
- rest.uniprot.org ↗ · 2026-11-10T21:11:38.339606+00:00
- rest.uniprot.org ↗ · 2026-11-10T21:11:38.378467+00:00
- rest.uniprot.org ↗ · 2026-11-10T21:11:38.407628+00:00
Recorded 2026-11-10. Source dates and identifiers are retained below.
Publications in this UniProt entry
1985 · Nature
PubMed 2867473 ↗Scope & authors
NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS ALPHA AND BETA)
Hollenberg S.M., Weinberger C., Ong E.S., Cerelli G., Oro A., Lebo R., Thompson E.B., Rosenfeld M.G., Evans R.M.
1991 · J. Biol. Chem.
PubMed 1707881 ↗Scope & authors
NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORMS ALPHA AND BETA)
Encio I.J., Detera-Wadleigh S.D.
2011 · Nucleic Acids Res.
PubMed 20843780 ↗Scope & authors
NUCLEOTIDE SEQUENCE [GENOMIC DNA]
Wang W., Shen P., Thiyagarajan S., Lin S., Palm C., Horvath R., Klopstock T., Cutler D., Pique L., Schrijver I., Davis R.W., Mindrinos M., Speed T.P., Scharfe C.
2007 · Ann. N. Y. Acad. Sci.
PubMed 17404046 ↗Scope & authors
NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 10)
Turner J.D., Schote A.B., Keipes M., Muller C.P.
All source publications (104)
2011 · Shock
PubMed 21701417 ↗Scope & authors
NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM ALPHA); VARIANTS ASP-72; ALA-321 AND SER-766; CHARACTERIZATION OF VARIANTS ASP-72; ALA-321 AND SER-766
Tung K., Baker A.C., Amini A., Green T.L., Chew V.W., Lim D., Nguyen S.T., Yee K.S., Cho K., Greenhalgh D.G.
SEP-1993 ·
Scope & authors
NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM ALPHA-2)
Munroe D.G., Pang J., Taylor G.R., Lau C., Plante R.K., Zhou L.
APR-2005 ·
Scope & authors
NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM ALPHA)
Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S.
2007 · BMC Genomics
PubMed 17974005 ↗Scope & authors
NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM ALPHA)
Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U., Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D., Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A., Wiemann S., Schupp I.
OCT-2003 ·
Scope & authors
NUCLEOTIDE SEQUENCE [GENOMIC DNA]; VARIANTS LYS-23 AND VAL-65
FEB-2007 ·
Scope & authors
NUCLEOTIDE SEQUENCE [GENOMIC DNA]
2004 · Nature
PubMed 15372022 ↗Scope & authors
NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]
Schmutz J., Martin J., Terry A., Couronne O., Grimwood J., Lowry S., Gordon L.A., Scott D., Xie G., Huang W., Hellsten U., Tran-Gyamfi M., She X., Prabhakar S., Aerts A., Altherr M., Bajorek E., Black S., Branscomb E., Caoile C., Challacombe J.F., Chan Y.M., Denys M., Detter J.C., Escobar J., Flowers D., Fotopulos D., Glavina T., Gomez M., Gonzales E., Goodstein D., Grigoriev I., Groza M., Hammon N., Hawkins T., Haydu L., Israni S., Jett J., Kadner K., Kimball H., Kobayashi A., Lopez F., Lou Y., Martinez D., Medina C., Morgan J., Nandkeshwar R., Noonan J.P., Pitluck S., Pollard M., Predki P., Priest J., Ramirez L., Retterer J., Rodriguez A., Rogers S., Salamov A., Salazar A., Thayer N., Tice H., Tsai M., Ustaszewska A., Vo N., Wheeler J., Wu K., Yang J., Dickson M., Cheng J.-F., Eichler E.E., Olsen A., Pennacchio L.A., Rokhsar D.S., Richardson P., Lucas S.M., Myers R.M., Rubin E.M.
SEP-2005 ·
Scope & authors
NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]
Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W., Venter J.C.
2004 · Genome Res.
PubMed 15489334 ↗Scope & authors
NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM ALPHA)
1991 · J. Biol. Chem.
PubMed 2026589 ↗Scope & authors
NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-394
Leclerc S., Xie B.X., Roy R., Govindan M.V.
1991 · J. Steroid Biochem. Mol. Biol.
PubMed 1958537 ↗Scope & authors
NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-394
Govindan M.V., Pothier F., Leclerc S., Palaniswami R., Xie B.
1985 · Nature
PubMed 3841189 ↗Scope & authors
DOMAINS
Weinberger C., Hollenberg S.M., Rosenfeld M.G., Evans R.M.
1993 · Cancer Res.
PubMed 8358712 ↗Scope & authors
ALTERNATIVE SPLICING (ISOFORMS GR-P; GR-A ALPHA AND GR-A BETA)
Moalli P.A., Pillay S., Krett N.L., Rosen S.T.
1995 · J. Clin. Invest.
PubMed 7769088 ↗Scope & authors
FUNCTION (ISOFORM BETA); TISSUE SPECIFICITY (ISOFORM BETA)
Bamberger C.M., Bamberger A.M., de Castro M., Chrousos G.P.
1996 · J. Biol. Chem.
PubMed 8621628 ↗Scope & authors
FUNCTION (ISOFORM BETA); SUBCELLULAR LOCATION (ISOFORMS ALPHA AND BETA); TISSUE SPECIFICITY (ISOFORM BETA)
Oakley R.H., Sar M., Cidlowski J.A.
1997 · J. Biol. Chem.
PubMed 9353307 ↗Scope & authors
INTERACTION WITH HNRNPU
Eggert M., Michel J., Schneider S., Bornfleth H., Baniahmad A., Fackelmayer F.O., Schmidt S., Renkawitz R.
1997 · Mol. Cell. Biol.
PubMed 9154805 ↗Scope & authors
INTERACTION WITH TADA2L AND THE ADA COMPLEX; MUTAGENESIS OF PHE-191; ILE-193; LEU-194; LEU-197; TRP-213; LEU-224; LEU-225; PHE-235 AND LEU-236
Henriksson A., Almloef T., Ford J., McEwan I.J., Gustafsson J.-A., Wright A.P.H.
1998 · Nature
PubMed 9590696 ↗Scope & authors
FUNCTION; INTERACTION WITH THE SMARCA4 COMPLEX; NCOA1; NCOA2 AND THE CREBBP/EP300 COMPLEX
Fryer C.J., Archer T.K.
1999 · J. Cell Biol.
PubMed 10477749 ↗Scope & authors
INTERACTION WITH BAG1
Schneikert J., Huebner S., Martin E., Cato A.B.C.
1999 · J. Clin. Endocrinol. Metab.
PubMed 10566686 ↗Scope & authors
ALTERNATIVE SPLICING (ISOFORMS ALPHA-2 AND BETA-2); TISSUE SPECIFICITY (ISOFORM ALPHA-2)
Rivers C., Levy A., Hancock J., Lightman S., Norman M.
2000 · J. Clin. Endocrinol. Metab.
PubMed 10902803 ↗Scope & authors
TISSUE SPECIFICITY
Kayes-Wandover K.M., White P.C.
2000 · Mol. Cell. Biol.
PubMed 10866662 ↗Scope & authors
INTERACTION WITH NCOA6
Mahajan M.A., Samuels H.H.
2000 · Proc. Natl. Acad. Sci. U.S.A.
PubMed 10639135 ↗Scope & authors
EFFECT ON EXPANDED POLYGLUTAMINE PROTEIN
Diamond M.I., Robinson M.R., Yamamoto K.R.
2001 · Cancer Res.
PubMed 11358809 ↗Scope & authors
FUNCTION (ISOFORM GR-P)
de Lange P., Segeren C.M., Koper J.W., Wiemer E., Sonneveld P., Brinkmann A.O., White A., Brogan I.J., de Jong F.H., Lamberts S.W.
2001 · J. Biol. Chem.
PubMed 11555652 ↗Scope & authors
GLUCOCORTICOID-MEDIATED DOWN-REGULATION
Wallace A.D., Cidlowski J.A.
2001 · J. Exp. Med.
PubMed 11238589 ↗Scope & authors
REDUCTION OF CELL DEATH IN RESPONSE TO CORTICOSTEROIDS
Strickland I., Kisich K., Hauk P.J., Vottero A., Chrousos G.P., Klemm D.J., Leung D.Y.M.
2001 · Mol. Endocrinol.
PubMed 11435610 ↗Scope & authors
FUNCTION (ISOFORMS ALPHA AND ALPHA-B); ALTERNATIVE INITIATION; MUTAGENESIS OF MET-1 AND MET-27
Yudt M.R., Cidlowski J.A.
2001 · Proc. Natl. Acad. Sci. U.S.A.
PubMed 11381138 ↗Scope & authors
INDUCTION (ISOFORMS ALPHA AND BETA)
Webster J.C., Oakley R.H., Jewell C.M., Cidlowski J.A.
2002 · Biochem. J.
PubMed 12144530 ↗Scope & authors
SUMOYLATION; MUTAGENESIS OF LYS-277; LYS-293 AND LYS-703
Tian S., Poukka H., Palvimo J.J., Jaenne O.A.
2002 · J. Biol. Chem.
PubMed 12000743 ↗Scope & authors
PHOSPHORYLATION AT SER-203 AND SER-211
Wang Z., Frederick J., Garabedian M.J.
2002 · Proc. Natl. Acad. Sci. U.S.A.
PubMed 12415108 ↗Scope & authors
RETRACTED PAPER
Wong C.-W., McNally C., Nickbarg E., Komm B.S., Cheskis B.J.
2009 · Proc. Natl. Acad. Sci. U.S.A.
PubMed 19666546 ↗Scope & authors
RETRACTION NOTICE OF PUBMED:12415108
Wong C.W., McNally C., Nickbarg E., Komm B.S., Cheskis B.J.
2004 · Ann. N. Y. Acad. Sci.
PubMed 15265776 ↗Scope & authors
REVIEW ON ALTERNATIVE SPLICING; ALTERNATIVE INITIATION
Lu N.Z., Cidlowski J.A.
2004 · J. Cell. Biochem.
PubMed 15211577 ↗Scope & authors
INTERACTION WITH TGFB1I1
Guerrero-Santoro J., Yang L., Stallcup M.R., DeFranco D.B.
2005 · Mol. Cell
PubMed 15866175 ↗Scope & authors
FUNCTION (ISOFORMS ALPHA; ALPHA-B; ALPHA-C1; ALPHA-C2; ALPHA-C3; ALPHA-D1; ALPHA-D2 AND ALPHA-D3); SUBCELLULAR LOCATION (ISOFORM ALPHA-B); ALTERNATIVE INITIATION (ISOFORMS ALPHA; ALPHA-B; ALPHA-C1; ALPHA-C2; ALPHA-C3; ALPHA-D1; ALPHA-D2 AND ALPHA-D3); MUTAGENESIS OF MET-1; MET-27; MET-86; MET-90; MET-98; MET-316; MET-331 AND MET-336
Lu N.Z., Cidlowski J.A.
2005 · Mol. Endocrinol.
PubMed 15591535 ↗Scope & authors
INTERACTION WITH NR4A3
Martens C., Bilodeau S., Maira M., Gauthier Y., Drouin J.
2005 · Proc. Natl. Acad. Sci. U.S.A.
PubMed 15941832 ↗Scope & authors
INTERACTION WITH HEXIM1
Shimizu N., Ouchida R., Yoshikawa N., Hisada T., Watanabe H., Okamoto K., Kusuhara M., Handa H., Morimoto C., Tanaka H.
2006 · Biochem. Biophys. Res. Commun.
PubMed 16914116 ↗Scope & authors
INTERACTION WITH MCM3AP
Osman W., Laine S., Zilliacus J.
2006 · Mol. Cell. Biol.
PubMed 16478993 ↗Scope & authors
INTERACTION WITH UNC45A
Chadli A., Graham J.D., Abel M.G., Jackson T.A., Gordon D.F., Wood W.M., Felts S.J., Horwitz K.B., Toft D.
2006 · Nat. Biotechnol.
PubMed 16964243 ↗Scope & authors
IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]
Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.
2008 · Mol. Cell
PubMed 18691976 ↗Scope & authors
IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]
Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., Greff Z., Keri G., Stemmann O., Mann M.
2008 · Mol. Cell. Biol.
PubMed 18838540 ↗Scope & authors
INTERACTION WITH GSK3B; SUBCELLULAR LOCATION (ISOFORM ALPHA); PHOSPHORYLATION AT SER-404; MUTAGENESIS OF SER-404; IDENTIFICATION BY MASS SPECTROMETRY
Galliher-Beckley A.J., Williams J.G., Collins J.B., Cidlowski J.A.
2008 · Mol. Endocrinol.
PubMed 18483179 ↗Scope & authors
PHOSPHORYLATION AT SER-203; SER-211 AND SER-226; MUTAGENESIS OF SER-211 AND SER-226
Chen W., Dang T., Blind R.D., Wang Z., Cavasotto C.N., Hittelman A.B., Rogatsky I., Logan S.K., Garabedian M.J.
2008 · Proc. Natl. Acad. Sci. U.S.A.
PubMed 18669648 ↗Scope & authors
PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-134; SER-226 AND SER-267; IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]
Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., Elledge S.J., Gygi S.P.
2009 · Biochem. Biophys. Res. Commun.
PubMed 19248771 ↗Scope & authors
FUNCTION (ISOFORMS ALPHA AND BETA); SUBCELLULAR LOCATION (ISOFORM BETA)
Kino T., Manoli I., Kelkar S., Wang Y., Su Y.A., Chrousos G.P.
2009 · FASEB J.
PubMed 19141540 ↗Scope & authors
FUNCTION (ISOFORM ALPHA); ACETYLATION AT LYS-480; LYS-492; LYS-494 AND LYS-495; MUTAGENESIS OF LYS-480; LYS-492; LYS-494 AND LYS-495; INTERACTION WITH CLOCK
Nader N., Chrousos G.P., Kino T.
2009 · Sci. Signal.
PubMed 19690332 ↗Scope & authors
IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]
Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., Rodionov V., Han D.K.
2010 · BMC Mol. Biol.
PubMed 20078863 ↗Scope & authors
INTERACTION WITH TACC1
Guyot R., Vincent S., Bertin J., Samarut J., Ravel-Chapuis P.
2010 · Endocrinology
PubMed 20484466 ↗Scope & authors
FUNCTION (ISOFORMS ALPHA; BETA; ALPHA-2 AND 10)
Taniguchi Y., Iwasaki Y., Tsugita M., Nishiyama M., Taguchi T., Okazaki M., Nakayama S., Kambayashi M., Hashimoto K., Terada Y.
2010 · Sci. Signal.
PubMed 20068231 ↗Scope & authors
IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]
Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.
2011 · BMC Syst. Biol.
PubMed 21269460 ↗Scope & authors
IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]
Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.
2011 · Biochim. Biophys. Acta
PubMed 21664385 ↗Scope & authors
FUNCTION (ISOFORM ALPHA); SUBCELLULAR LOCATION (ISOFORM ALPHA)
Psarra A.M., Sekeris C.E.
2011 · J. Biol. Chem.
PubMed 21730050 ↗Scope & authors
SUBUNIT
Gallo L.I., Lagadari M., Piwien-Pilipuk G., Galigniana M.D.
2011 · Nature
PubMed 22170608 ↗Scope & authors
INTERACTION WITH CRY1 AND CRY2
Lamia K.A., Papp S.J., Yu R.T., Barish G.D., Uhlenhaut N.H., Jonker J.W., Downes M., Evans R.M.
2011 · PLoS ONE
PubMed 21980503 ↗Scope & authors
ACETYLATION; INTERACTION WITH CLOCK
Charmandari E., Chrousos G.P., Lambrou G.I., Pavlaki A., Koide H., Ng S.S., Kino T.
2012 · Proc. Natl. Acad. Sci. U.S.A.
PubMed 22814378 ↗Scope & authors
ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1 (ISOFORMS ALPHA-B AND BETA-B); IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]
Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A., Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E., Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.
2013 · Cell Death Dis.
PubMed 23303127 ↗Scope & authors
FUNCTION (ISOFORMS ALPHA; ALPHA-C3 AND ALPHA-D3)
Wu I., Shin S.C., Cao Y., Bender I.K., Jafari N., Feng G., Lin S., Cidlowski J.A., Schleimer R.P., Lu N.Z.
2013 · J. Proteome Res.
PubMed 23186163 ↗Scope & authors
PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-8; SER-45 AND SER-267; IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]
Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., Mohammed S.
2013 · Mol. Cell. Biol.
PubMed 23508108 ↗Scope & authors
MUTAGENESIS OF LYS-703
Druker J., Liberman A.C., Antunica-Noguerol M., Gerez J., Paez-Pereda M., Rein T., Iniguez-Lluhi J.A., Holsboer F., Arzt E.
2013 · Mol. Endocrinol.
PubMed 23820903 ↗Scope & authors
FUNCTION (ISOFORMS ALPHA; ALPHA-C3 AND ALPHA-D3); MUTAGENESIS OF ASP-101; 106-GLN-GLN-107 AND 113-SER-SER-114
Bender I.K., Cao Y., Lu N.Z.
2014 · J. Proteomics
PubMed 24275569 ↗Scope & authors
PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-203; IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]
Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., Ye M., Zou H.
2014 · Proc. Natl. Acad. Sci. U.S.A.
PubMed 25114211 ↗Scope & authors
SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-293; IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]
Impens F., Radoshevich L., Cossart P., Ribet D.
2015 · Mol. Cell. Biol.
PubMed 26711253 ↗Scope & authors
FUNCTION (ISOFORM BETA); SUBCELLULAR LOCATION (ISOFORM BETA)
He B., Cruz-Topete D., Oakley R.H., Xiao X., Cidlowski J.A.
2015 · Proc. Natl. Acad. Sci. U.S.A.
PubMed 25775514 ↗Scope & authors
FUNCTION; INTERACTION WITH PNRC2
Cho H., Park O.H., Park J., Ryu I., Kim J., Ko J., Kim Y.K.
2015 · Proc. Natl. Acad. Sci. U.S.A.
PubMed 25847991 ↗Scope & authors
FUNCTION (ISOFORM ALPHA); SUBCELLULAR LOCATION (ISOFORM ALPHA); TISSUE SPECIFICITY; DOMAIN; PHOSPHORYLATION AT SER-203 AND SER-211
Matthews L.C., Berry A.A., Morgan D.J., Poolman T.M., Bauer K., Kramer F., Spiller D.G., Richardson R.V., Chapman K.E., Farrow S.N., Norman M.R., Williamson A.J., Whetton A.D., Taylor S.S., Tuckermann J.P., White M.R., Ray D.W.
2016 · Nat. Commun.
PubMed 27353360 ↗Scope & authors
INTERACTION WITH FNIP1 AND FNIP2
Woodford M.R., Dunn D.M., Blanden A.R., Capriotti D., Loiselle D., Prodromou C., Panaretou B., Hughes P.F., Smith A., Ackerman W., Haystead T.A., Loh S.N., Bourboulia D., Schmidt L.S., Marston Linehan W., Bratslavsky G., Mollapour M.
2017 · EMBO J.
PubMed 29127155 ↗Scope & authors
IDENTIFICATION IN A COMPLEX WITH HSP90; HSP70; CDC37; PPP5C; TSC1; TSC2; AKT; CDK4 AND RAF1
Woodford M.R., Sager R.A., Marris E., Dunn D.M., Blanden A.R., Murphy R.L., Rensing N., Shapiro O., Panaretou B., Prodromou C., Loh S.N., Gutmann D.H., Bourboulia D., Bratslavsky G., Wong M., Mollapour M.
2017 · Nat. Struct. Mol. Biol.
PubMed 28112733 ↗Scope & authors
SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-258 AND LYS-277; IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]
Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C., Nielsen M.L.
2017 · Sci. Rep.
PubMed 28139699 ↗Scope & authors
FUNCTION; INTERACTION WITH ZNF764
Fadda A., Syed N., Mackeh R., Papadopoulou A., Suzuki S., Jithesh P.V., Kino T.
2023 · Mol. Cell
PubMed 37478846 ↗Scope & authors
FUNCTION; UBIQUITINATION
Tsai J.M., Aguirre J.D., Li Y.D., Brown J., Focht V., Kater L., Kempf G., Sandoval B., Schmitt S., Rutter J.C., Galli P., Sandate C.R., Cutler J.A., Zou C., Donovan K.A., Lumpkin R.J., Cavadini S., Park P.M.C., Sievers Q., Hatton C., Ener E., Regalado B.D., Sperling M.T., Slabicki M., Kim J., Zon R., Zhang Z., Miller P.G., Belizaire R., Sperling A.S., Fischer E.S., Irizarry R., Armstrong S.A., Thomae N.H., Ebert B.L.
2002 · Cell
PubMed 12151000 ↗Scope & authors
X-RAY CRYSTALLOGRAPHY OF MUTANT SER-602 IN COMPLEX WITH NCOA2; DEXAMETHASONE AND RU-486; MUTAGENESIS OF ARG-585; ASP-590; PHE-602; PRO-625 AND ILE-628
Bledsoe R.K., Montana V.G., Stanley T.B., Delves C.J., Apolito C.J., McKee D.D., Consler T.G., Parks D.J., Stewart E.L., Willson T.M., Lambert M.H., Moore J.T., Pearce K.H., Xu H.E.
2003 · J. Biol. Chem.
PubMed 12686538 ↗Scope & authors
X-RAY CRYSTALLOGRAPHY OF MUTANT SER-602 IN COMPLEX WITH COACTIVATOR PEPTIDE; DEXAMETHASONE AND WITH RU-486
Kauppi B., Jakob C., Faernegaardh M., Yang J., Ahola H., Alarcon M., Calles K., Engstrom O., Harlan J., Muchmore S., Ramqvist A.-K., Thorell S., Oehman L., Greer J., Gustafsson J.-A., Carlstedt-Duke J., Carlquist M.
1991 · J. Clin. Invest.
PubMed 1704018 ↗Scope & authors
CHARACTERIZATION OF VARIANT GCCR VAL-641
Hurley D.M., Accili D., Stratakis C.A., Karl M., Vamvakopoulos N., Rorer E., Constantine K., Taylor S.I., Chrousos G.P.
1993 · Cancer Res.
PubMed 8358735 ↗Scope & authors
VARIANTS TYR-421 AND PHE-753
Powers J.H., Hillmann A.G., Tang D.C., Harmon J.M.
1993 · J. Clin. Endocrinol. Metab.
PubMed 8445027 ↗Scope & authors
VARIANT SER-363
Karl M., Lamberts S.W.J., Detera-Wadleigh S.D., Encio I.J., Stratakis C.A., Hurley D.M., Accili D., Chrousos G.P.
1993 · J. Clin. Invest.
PubMed 7683692 ↗Scope & authors
VARIANT GCCR ILE-729
Malchoff D.M., Brufsky A., Reardon G., McDermott P., Javier E.C., Bergh C.H., Rowe D., Malchoff C.D.
1993 · Mol. Endocrinol.
PubMed 8316249 ↗Scope & authors
VARIANT PHE-753
Ashraf J., Thompson E.B.
1997 · Hum. Genet.
PubMed 9150737 ↗Scope & authors
VARIANTS LYS-23 AND SER-363
Koper J.W., Stolk R.P., de Lange P., Huizenga N.A.T.M., Molijn G.-J., Pols H.A.P., Grobbee D.E., Karl M., de Jong F.H., Brinkmann A.O., Lamberts S.W.J.
1999 · Nat. Genet.
PubMed 10391209 ↗Scope & authors
VARIANTS LYS-23; VAL-65 AND SER-363
Cargill M., Altshuler D., Ireland J., Sklar P., Ardlie K., Patil N., Shaw N., Lane C.R., Lim E.P., Kalyanaraman N., Nemesh J., Ziaugra L., Friedland L., Rolfe A., Warrington J., Lipshutz R., Daley G.Q., Lander E.S.
1999 · Nat. Genet.
Scope & authors
ERRATUM OF PUBMED:10391209
Cargill M., Altshuler D., Ireland J., Sklar P., Ardlie K., Patil N., Shaw N., Lane C.R., Lim E.P., Kalyanaraman N., Nemesh J., Ziaugra L., Friedland L., Rolfe A., Warrington J., Lipshutz R., Daley G.Q., Lander E.S.
2000 · Am. J. Med. Genet.
PubMed 10898924 ↗Scope & authors
VARIANTS LYS-23; LEU-29; PHE-112; ASN-233 AND SER-363
Feng J., Zheng J., Bennett W.P., Heston L.L., Jones I.R., Craddock N., Sommer S.S.
2001 · Clin. Endocrinol. (Oxf.)
PubMed 11589680 ↗Scope & authors
VARIANTS GCCR HIS-477 AND SER-679
Ruiz M., Lind U., Gaafvels M., Eggertsen G., Carlstedt-Duke J., Nilsson L., Holtmann M., Stierna P., Wikstroem A.-C., Werner S.
2001 · J. Clin. Endocrinol. Metab.
PubMed 11344238 ↗Scope & authors
VARIANT SER-363
Dobson M.G., Redfern C.P.F., Unwin N., Weaver J.U.
2001 · J. Clin. Endocrinol. Metab.
PubMed 11701741 ↗Scope & authors
CHARACTERIZATION OF VARIANT GCCR ASN-559
Kino T., Stauber R.H., Resau J.H., Pavlakis G.N., Chrousos G.P.
2002 · Diabetes
PubMed 12351458 ↗Scope & authors
VARIANT LYS-23
van Rossum E.F.C., Koper J.W., Huizenga N.A.T.M., Uitterlinden A.G., Janssen J.A.M.J.L., Brinkmann A.O., Grobbee D.E., de Jong F.H., van Duyn C.M., Pols H.A.P., Lamberts S.W.J.
2002 · J. Clin. Endocrinol. Metab.
PubMed 11932321 ↗Scope & authors
VARIANT PSEUDOHERMAPHRODITISM ALA-571
Mendonca B.B., Leite M.V., de Castro M., Kino T., Elias L.L.K., Bachega T.A.S., Arnhold I.J.P., Chrousos G.P., Latronico A.C.
2002 · J. Clin. Endocrinol. Metab.
PubMed 12050230 ↗Scope & authors
VARIANT GCCR MET-747; ALTERED INTERACTION WITH THE COACTIVATOR NCOA2
Vottero A., Kino T., Combe H., Lecomte P., Chrousos G.P.
2004 · Am. J. Med.
PubMed 15276593 ↗Scope & authors
VARIANT LYS-23
van Rossum E.F.C., Feelders R.A., van den Beld A.W., Uitterlinden A.G., Janssen J.A.M.J.L., Ester W., Brinkmann A.O., Grobbee D.E., de Jong F.H., Pols H.A.P., Koper J.W., Lamberts S.W.J.
2004 · J. Clin. Endocrinol. Metab.
PubMed 15292341 ↗Scope & authors
VARIANT LYS-23
van Rossum E.F.C., Voorhoeve P.G., te Velde S.J., Koper J.W., Delemarre-van de Waal H.A., Kemper H.C.G., Lamberts S.W.J.
2005 · J. Clin. Endocrinol. Metab.
PubMed 15769988 ↗Scope & authors
VARIANT GCCR PRO-773; CHARACTERIZATION OF VARIANT GCCR PRO-773; INVOLVEMENT IN GCCR; FUNCTION (ISOFORM ALPHA); INTERACTION WITH GRIP1; SUBCELLULAR LOCATION (ISOFORM ALPHA)
Charmandari E., Raji A., Kino T., Ichijo T., Tiulpakov A., Zachman K., Chrousos G.P.
2005 · J. Clin. Endocrinol. Metab.
PubMed 16030164 ↗Scope & authors
VARIANTS LYS-23 AND SER-363; CHARACTERIZATION OF VARIANTS LYS-23 AND SER-363
Russcher H., Smit P., van den Akker E.L., van Rossum E.F., Brinkmann A.O., de Jong F.H., Lamberts S.W., Koper J.W.
2007 · J. Clin. Endocrinol. Metab.
PubMed 17635946 ↗Scope & authors
VARIANT GCCR LEU-737; CHARACTERIZATION OF VARIANT GCCR LEU-737; FUNCTION (ISOFORM ALPHA); INTERACTION WITH GRIP1; SUBCELLULAR LOCATION (ISOFORM ALPHA)
Charmandari E., Kino T., Ichijo T., Jubiz W., Mejia L., Zachman K., Chrousos G.P.
2010 · J. Clin. Endocrinol. Metab.
PubMed 20335448 ↗Scope & authors
VARIANT GCCR GLN-714; CHARACTERIZATION OF VARIANT GCCR GLN-714
Nader N., Bachrach B.E., Hurt D.E., Gajula S., Pittman A., Lescher R., Kino T.
2011 · Chin. Med. J.
PubMed 21362280 ↗Scope & authors
VARIANT GCCR ILE-556
Zhu H.J., Dai Y.F., Wang O., Li M., Lu L., Zhao W.G., Xing X.P., Pan H., Li N.S., Gong F.Y.
2013 · J. Clin. Endocrinol. Metab.
PubMed 23426617 ↗Scope & authors
CHARACTERIZATION OF VARIANT GCCR ALA-423
Roberts M.L., Kino T., Nicolaides N.C., Hurt D.E., Katsantoni E., Sertedaki A., Komianou F., Kassiou K., Chrousos G.P., Charmandari E.
2014 · J. Clin. Endocrinol. Metab.
PubMed 24483153 ↗Scope & authors
VARIANT GCCR GLY-575; CHARACTERIZATION OF VARIANT GCCR GLY-575
Nicolaides N.C., Roberts M.L., Kino T., Braatvedt G., Hurt D.E., Katsantoni E., Sertedaki A., Chrousos G.P., Charmandari E.
2015 · Eur. J. Clin. Invest.
PubMed 26031419 ↗Scope & authors
VARIANT GCCR ARG-726; CHARACTERIZATION OF VARIANT GCCR ARG-726
Nicolaides N.C., Geer E.B., Vlachakis D., Roberts M.L., Psarra A.M., Moutsatsou P., Sertedaki A., Kossida S., Charmandari E.
2016 · Eur. J. Clin. Invest.
PubMed 26541474 ↗Scope & authors
CHARACTERIZATION OF VARIANT GCCR ILE-556
Nicolaides N.C., Skyrla E., Vlachakis D., Psarra A.M., Moutsatsou P., Sertedaki A., Kossida S., Charmandari E.
2016 · Hum. Mutat.
PubMed 27120390 ↗Scope & authors
VARIANTS GCCR SER-477; CYS-478 AND PRO-672; CHARACTERIZATION OF VARIANTS GCCR SER-477; CYS-478 AND CYS-478; FUNCTION; SUBCELLULAR LOCATION
Vitellius G., Fagart J., Delemer B., Amazit L., Ramos N., Bouligand J., Le Billan F., Castinetti F., Guiochon-Mantel A., Trabado S., Lombes M.
2019 · Nucleic Acids Res.
PubMed 30698747 ↗Scope & authors
SUBCELLULAR LOCATION
Magomedova L., Tiefenbach J., Zilberman E., Le Billan F., Voisin V., Saikali M., Boivin V., Robitaille M., Gueroussov S., Irimia M., Ray D., Patel R., Xu C., Jeyasuria P., Bader G.D., Hughes T.R., Morris Q.D., Scott M.S., Krause H., Angers S., Blencowe B.J., Cummins C.L.
Annotation coverage audit
Every recorded UniProt comment and feature has a destination in this page. GO, Atlas annotations and interaction rows retain their separate source counts.
203 source comments and features accounted for.
View annotation inventory
| Source record | Type | Section |
|---|---|---|
| FUNCTION:0 | FUNCTION | function |
| FUNCTION:1 | FUNCTION | function |
| FUNCTION:2 | FUNCTION | function |
| FUNCTION:3 | FUNCTION | function |
| FUNCTION:4 | FUNCTION | function |
| FUNCTION:5 | FUNCTION | function |
| FUNCTION:6 | FUNCTION | function |
| FUNCTION:7 | FUNCTION | function |
| FUNCTION:8 | FUNCTION | function |
| FUNCTION:9 | FUNCTION | function |
| FUNCTION:10 | FUNCTION | function |
| FUNCTION:11 | FUNCTION | function |
| FUNCTION:12 | FUNCTION | function |
| SUBUNIT:0 | SUBUNIT | interactions |
| INTERACTION:0 | INTERACTION | interactions |
| SUBCELLULAR LOCATION:0 | SUBCELLULAR LOCATION | location |
| SUBCELLULAR LOCATION:1 | SUBCELLULAR LOCATION | location |
| SUBCELLULAR LOCATION:2 | SUBCELLULAR LOCATION | location |
| ALTERNATIVE PRODUCTS:0 | ALTERNATIVE PRODUCTS | sequence |
| TISSUE SPECIFICITY:0 | TISSUE SPECIFICITY | expression |
| TISSUE SPECIFICITY:1 | TISSUE SPECIFICITY | expression |
| TISSUE SPECIFICITY:2 | TISSUE SPECIFICITY | expression |
| INDUCTION:0 | INDUCTION | expression |
| INDUCTION:1 | INDUCTION | expression |
| DOMAIN:0 | DOMAIN | domains |
| PTM:0 | PTM | processing |
| PTM:1 | PTM | processing |
| PTM:2 | PTM | processing |
| PTM:3 | PTM | processing |
| PTM:4 | PTM | processing |
| POLYMORPHISM:0 | POLYMORPHISM | disease |
| DISEASE:0 | DISEASE | disease |
| MISCELLANEOUS:0 | MISCELLANEOUS | function |
| MISCELLANEOUS:1 | MISCELLANEOUS | function |
| MISCELLANEOUS:2 | MISCELLANEOUS | function |
| MISCELLANEOUS:3 | MISCELLANEOUS | function |
| MISCELLANEOUS:4 | MISCELLANEOUS | function |
| MISCELLANEOUS:5 | MISCELLANEOUS | function |
| MISCELLANEOUS:6 | MISCELLANEOUS | function |
| MISCELLANEOUS:7 | MISCELLANEOUS | function |
| MISCELLANEOUS:8 | MISCELLANEOUS | function |
| MISCELLANEOUS:9 | MISCELLANEOUS | function |
| MISCELLANEOUS:10 | MISCELLANEOUS | function |
| MISCELLANEOUS:11 | MISCELLANEOUS | function |
| MISCELLANEOUS:12 | MISCELLANEOUS | function |
| MISCELLANEOUS:13 | MISCELLANEOUS | function |
| MISCELLANEOUS:14 | MISCELLANEOUS | function |
| MISCELLANEOUS:15 | MISCELLANEOUS | function |
| SIMILARITY:0 | SIMILARITY | domains |
| CAUTION:0 | CAUTION | function |
| WEB RESOURCE:0 | WEB RESOURCE | sources |
| feature-0 | Chain | processing |
| feature-1 | Domain | domains |
| feature-2 | DNA binding | domains |
| feature-3 | Zinc finger | domains |
| feature-4 | Zinc finger | domains |
| feature-5 | Region | domains |
| feature-6 | Region | domains |
| feature-7 | Region | domains |
| feature-8 | Region | domains |
| feature-9 | Region | domains |
| feature-10 | Region | domains |
| feature-11 | Region | domains |
| feature-12 | Region | domains |
| feature-13 | Compositional bias | domains |
| feature-14 | Compositional bias | domains |
| feature-15 | Compositional bias | domains |
| feature-16 | Compositional bias | domains |
| feature-17 | Compositional bias | domains |
| feature-18 | Compositional bias | domains |
| feature-19 | Modified residue | processing |
| feature-20 | Modified residue | processing |
| feature-21 | Modified residue | processing |
| feature-22 | Modified residue | processing |
| feature-23 | Modified residue | processing |
| feature-24 | Modified residue | processing |
| feature-25 | Modified residue | processing |
| feature-26 | Modified residue | processing |
| feature-27 | Modified residue | processing |
| feature-28 | Modified residue | processing |
| feature-29 | Modified residue | processing |
| feature-30 | Modified residue | processing |
| feature-31 | Modified residue | processing |
| feature-32 | Modified residue | processing |
| feature-33 | Modified residue | processing |
| feature-34 | Cross-link | processing |
| feature-35 | Cross-link | processing |
| feature-36 | Cross-link | processing |
| feature-37 | Cross-link | processing |
| feature-38 | Cross-link | processing |
| feature-39 | Cross-link | processing |
| feature-40 | Cross-link | processing |
| feature-41 | Alternative sequence | sequence |
| feature-42 | Alternative sequence | sequence |
| feature-43 | Alternative sequence | sequence |
| feature-44 | Alternative sequence | sequence |
| feature-45 | Alternative sequence | sequence |
| feature-46 | Alternative sequence | sequence |
| feature-47 | Alternative sequence | sequence |
| feature-48 | Alternative sequence | sequence |
| feature-49 | Alternative sequence | sequence |
| feature-50 | Alternative sequence | sequence |
| feature-51 | Alternative sequence | sequence |
| feature-52 | Natural variant | disease |
| feature-53 | Natural variant | disease |
| feature-54 | Natural variant | disease |
| feature-55 | Natural variant | disease |
| feature-56 | Natural variant | disease |
| feature-57 | Natural variant | disease |
| feature-58 | Natural variant | disease |
| feature-59 | Natural variant | disease |
| feature-60 | Natural variant | disease |
| feature-61 | Natural variant | disease |
| feature-62 | Natural variant | disease |
| feature-63 | Natural variant | disease |
| feature-64 | Natural variant | disease |
| feature-65 | Natural variant | disease |
| feature-66 | Natural variant | disease |
| feature-67 | Natural variant | disease |
| feature-68 | Natural variant | disease |
| feature-69 | Natural variant | disease |
| feature-70 | Natural variant | disease |
| feature-71 | Natural variant | disease |
| feature-72 | Natural variant | disease |
| feature-73 | Natural variant | disease |
| feature-74 | Natural variant | disease |
| feature-75 | Natural variant | disease |
| feature-76 | Natural variant | disease |
| feature-77 | Natural variant | disease |
| feature-78 | Natural variant | disease |
| feature-79 | Natural variant | disease |
| feature-80 | Mutagenesis | disease |
| feature-81 | Mutagenesis | disease |
| feature-82 | Mutagenesis | disease |
| feature-83 | Mutagenesis | disease |
| feature-84 | Mutagenesis | disease |
| feature-85 | Mutagenesis | disease |
| feature-86 | Mutagenesis | disease |
| feature-87 | Mutagenesis | disease |
| feature-88 | Mutagenesis | disease |
| feature-89 | Mutagenesis | disease |
| feature-90 | Mutagenesis | disease |
| feature-91 | Mutagenesis | disease |
| feature-92 | Mutagenesis | disease |
| feature-93 | Mutagenesis | disease |
| feature-94 | Mutagenesis | disease |
| feature-95 | Mutagenesis | disease |
| feature-96 | Mutagenesis | disease |
| feature-97 | Mutagenesis | disease |
| feature-98 | Mutagenesis | disease |
| feature-99 | Mutagenesis | disease |
| feature-100 | Mutagenesis | disease |
| feature-101 | Mutagenesis | disease |
| feature-102 | Mutagenesis | disease |
| feature-103 | Mutagenesis | disease |
| feature-104 | Mutagenesis | disease |
| feature-105 | Mutagenesis | disease |
| feature-106 | Mutagenesis | disease |
| feature-107 | Mutagenesis | disease |
| feature-108 | Mutagenesis | disease |
| feature-109 | Mutagenesis | disease |
| feature-110 | Mutagenesis | disease |
| feature-111 | Mutagenesis | disease |
| feature-112 | Mutagenesis | disease |
| feature-113 | Mutagenesis | disease |
| feature-114 | Mutagenesis | disease |
| feature-115 | Mutagenesis | disease |
| feature-116 | Mutagenesis | disease |
| feature-117 | Sequence conflict | sequence |
| feature-118 | Sequence conflict | sequence |
| feature-119 | Helix | sequence |
| feature-120 | Turn | sequence |
| feature-121 | Beta strand | sequence |
| feature-122 | Beta strand | sequence |
| feature-123 | Helix | sequence |
| feature-124 | Beta strand | sequence |
| feature-125 | Turn | sequence |
| feature-126 | Helix | sequence |
| feature-127 | Helix | sequence |
| feature-128 | Helix | sequence |
| feature-129 | Beta strand | sequence |
| feature-130 | Helix | sequence |
| feature-131 | Helix | sequence |
| feature-132 | Beta strand | sequence |
| feature-133 | Helix | sequence |
| feature-134 | Helix | sequence |
| feature-135 | Helix | sequence |
| feature-136 | Beta strand | sequence |
| feature-137 | Beta strand | sequence |
| feature-138 | Beta strand | sequence |
| feature-139 | Helix | sequence |
| feature-140 | Helix | sequence |
| feature-141 | Helix | sequence |
| feature-142 | Beta strand | sequence |
| feature-143 | Helix | sequence |
| feature-144 | Beta strand | sequence |
| feature-145 | Helix | sequence |
| feature-146 | Helix | sequence |
| feature-147 | Helix | sequence |
| feature-148 | Helix | sequence |
| feature-149 | Beta strand | sequence |
| feature-150 | Modified residue | processing |
| feature-151 | Modified residue | processing |